US20200147032A1 - Dihydromyricetin hot melt extrusion formulations and methods for forming them - Google Patents
Dihydromyricetin hot melt extrusion formulations and methods for forming them Download PDFInfo
- Publication number
- US20200147032A1 US20200147032A1 US16/683,387 US201916683387A US2020147032A1 US 20200147032 A1 US20200147032 A1 US 20200147032A1 US 201916683387 A US201916683387 A US 201916683387A US 2020147032 A1 US2020147032 A1 US 2020147032A1
- Authority
- US
- United States
- Prior art keywords
- dhm
- formulation
- dihydromyricetin
- poly
- matrix material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- KJXSIXMJHKAJOD-LSDHHAIUSA-N (+)-dihydromyricetin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC(O)=C(O)C(O)=C1 KJXSIXMJHKAJOD-LSDHHAIUSA-N 0.000 title claims abstract description 817
- KQILIWXGGKGKNX-UHFFFAOYSA-N dihydromyricetin Natural products OC1C(=C(Oc2cc(O)cc(O)c12)c3cc(O)c(O)c(O)c3)O KQILIWXGGKGKNX-UHFFFAOYSA-N 0.000 title claims abstract description 408
- 239000000203 mixture Substances 0.000 title claims abstract description 267
- 238000000034 method Methods 0.000 title claims abstract description 40
- 238000009472 formulation Methods 0.000 title claims description 232
- 238000009474 hot melt extrusion Methods 0.000 title abstract description 79
- -1 carboxymethyl ethylcellulose Chemical compound 0.000 claims description 88
- 239000011159 matrix material Substances 0.000 claims description 75
- 229920000642 polymer Polymers 0.000 claims description 62
- 239000004014 plasticizer Substances 0.000 claims description 49
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 46
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 46
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 46
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 40
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 38
- 239000002552 dosage form Substances 0.000 claims description 37
- 150000001768 cations Chemical class 0.000 claims description 35
- 239000000843 powder Substances 0.000 claims description 32
- 229940074982 poly(vinylpyrrolidone-co-vinyl-acetate) Drugs 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 23
- 208000007848 Alcoholism Diseases 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 229920001577 copolymer Polymers 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 17
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 17
- 235000000346 sugar Nutrition 0.000 claims description 17
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- 239000004359 castor oil Substances 0.000 claims description 16
- 229920002301 cellulose acetate Polymers 0.000 claims description 16
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 16
- 229930195729 fatty acid Natural products 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 239000001768 carboxy methyl cellulose Chemical class 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 14
- 239000002184 metal Substances 0.000 claims description 14
- 229920000609 methyl cellulose Polymers 0.000 claims description 14
- 235000010981 methylcellulose Nutrition 0.000 claims description 14
- 239000001923 methylcellulose Substances 0.000 claims description 14
- 206010019133 Hangover Diseases 0.000 claims description 13
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
- 239000001913 cellulose Substances 0.000 claims description 13
- 235000010980 cellulose Nutrition 0.000 claims description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 claims description 12
- 235000019438 castor oil Nutrition 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 125000005395 methacrylic acid group Chemical group 0.000 claims description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 12
- 239000006179 pH buffering agent Substances 0.000 claims description 12
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 12
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 12
- 229920005862 polyol Polymers 0.000 claims description 12
- 150000003077 polyols Chemical class 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 235000010356 sorbitol Nutrition 0.000 claims description 12
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 11
- 238000009505 enteric coating Methods 0.000 claims description 11
- 239000002702 enteric coating Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 238000013329 compounding Methods 0.000 claims description 10
- 238000002844 melting Methods 0.000 claims description 10
- 230000008018 melting Effects 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant effect Effects 0.000 claims description 9
- 235000006708 antioxidants Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 9
- 239000011777 magnesium Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Chemical class 0.000 claims description 8
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 8
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 8
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 8
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 claims description 8
- 229960004308 acetylcysteine Drugs 0.000 claims description 8
- 201000007930 alcohol dependence Diseases 0.000 claims description 8
- 208000025746 alcohol use disease Diseases 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Chemical class 0.000 claims description 8
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 8
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 229920001610 polycaprolactone Polymers 0.000 claims description 8
- 229920000193 polymethacrylate Polymers 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940046009 vitamin E Drugs 0.000 claims description 8
- 239000001993 wax Substances 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004632 polycaprolactone Substances 0.000 claims description 7
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 6
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 239000005977 Ethylene Substances 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920002675 Polyoxyl Polymers 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 5
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- 150000003712 vitamin E derivatives Chemical class 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 4
- JOLQKTGDSGKSKJ-UHFFFAOYSA-N 1-ethoxypropan-2-ol Chemical compound CCOCC(C)O JOLQKTGDSGKSKJ-UHFFFAOYSA-N 0.000 claims description 4
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 claims description 4
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 4
- ZFEKANLLFQEKED-UHFFFAOYSA-N 2-propan-2-yloxypropan-1-ol Chemical compound CC(C)OC(C)CO ZFEKANLLFQEKED-UHFFFAOYSA-N 0.000 claims description 4
- 208000035143 Bacterial infection Diseases 0.000 claims description 4
- MRABAEUHTLLEML-UHFFFAOYSA-N Butyl lactate Chemical compound CCCCOC(=O)C(C)O MRABAEUHTLLEML-UHFFFAOYSA-N 0.000 claims description 4
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 108010024636 Glutathione Proteins 0.000 claims description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 229920002292 Nylon 6 Polymers 0.000 claims description 4
- 240000001439 Opuntia Species 0.000 claims description 4
- 235000013389 Opuntia humifusa var. humifusa Nutrition 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- 229920001100 Polydextrose Polymers 0.000 claims description 4
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UHFFFAOYSA-N Rohrzucker Natural products OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 claims description 4
- 241000320380 Silybum Species 0.000 claims description 4
- 235000010841 Silybum marianum Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 4
- ZAKOWWREFLAJOT-ADUHFSDSSA-N [2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] acetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-ADUHFSDSSA-N 0.000 claims description 4
- ZNPLZHBZUSCANM-UHFFFAOYSA-N acetic acid;benzene-1,3-dicarboxylic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC(C(O)=O)=C1 ZNPLZHBZUSCANM-UHFFFAOYSA-N 0.000 claims description 4
- FMTQGBMMIVVKSN-UHFFFAOYSA-N acetic acid;terephthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=C(C(O)=O)C=C1 FMTQGBMMIVVKSN-UHFFFAOYSA-N 0.000 claims description 4
- 150000005215 alkyl ethers Chemical class 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 4
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 claims description 4
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 4
- JEJBBWQXAMSBQT-UHFFFAOYSA-N butanedioic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)CCC(O)=O JEJBBWQXAMSBQT-UHFFFAOYSA-N 0.000 claims description 4
- 239000001191 butyl (2R)-2-hydroxypropanoate Substances 0.000 claims description 4
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 4
- 239000001354 calcium citrate Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000004203 carnauba wax Substances 0.000 claims description 4
- 235000013869 carnauba wax Nutrition 0.000 claims description 4
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 4
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 4
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- ZANNOFHADGWOLI-UHFFFAOYSA-N ethyl 2-hydroxyacetate Chemical compound CCOC(=O)CO ZANNOFHADGWOLI-UHFFFAOYSA-N 0.000 claims description 4
- 229940116333 ethyl lactate Drugs 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 claims description 4
- 239000001087 glyceryl triacetate Substances 0.000 claims description 4
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 4
- 235000019534 high fructose corn syrup Nutrition 0.000 claims description 4
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 4
- 239000000832 lactitol Substances 0.000 claims description 4
- 235000010448 lactitol Nutrition 0.000 claims description 4
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 4
- 229960003451 lactitol Drugs 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 230000004112 neuroprotection Effects 0.000 claims description 4
- 229960002446 octanoic acid Drugs 0.000 claims description 4
- KQOCPYKMLMTOOP-UHFFFAOYSA-N phthalic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O KQOCPYKMLMTOOP-UHFFFAOYSA-N 0.000 claims description 4
- 235000013856 polydextrose Nutrition 0.000 claims description 4
- 239000001259 polydextrose Substances 0.000 claims description 4
- 229940035035 polydextrose Drugs 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000001508 potassium citrate Substances 0.000 claims description 4
- 229960002635 potassium citrate Drugs 0.000 claims description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 4
- 235000011082 potassium citrates Nutrition 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 229960005480 sodium caprylate Drugs 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 4
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 claims description 4
- 229960002920 sorbitol Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 229960002622 triacetin Drugs 0.000 claims description 4
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 4
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 4
- 239000001069 triethyl citrate Substances 0.000 claims description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000013769 triethyl citrate Nutrition 0.000 claims description 4
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005591 trimellitate group Chemical group 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- 239000000811 xylitol Substances 0.000 claims description 4
- 235000010447 xylitol Nutrition 0.000 claims description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 4
- 229960002675 xylitol Drugs 0.000 claims description 4
- 229960003487 xylose Drugs 0.000 claims description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 239000012943 hotmelt Substances 0.000 description 35
- 239000000546 pharmaceutical excipient Substances 0.000 description 29
- 239000012530 fluid Substances 0.000 description 28
- 239000003814 drug Substances 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 23
- 229940079593 drug Drugs 0.000 description 18
- 239000008186 active pharmaceutical agent Substances 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 238000007922 dissolution test Methods 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000001125 extrusion Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000009477 glass transition Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 241001489705 Aquarius Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000007888 film coating Substances 0.000 description 5
- 238000009501 film coating Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 229920003083 Kollidon® VA64 Polymers 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004913 chyme Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 229920001169 thermoplastic Polymers 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
- 244000148064 Enicostema verticillatum Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000405398 Hovenia Species 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 206010027626 Milia Diseases 0.000 description 2
- 229920003072 Plasdone™ povidone Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001531 copovidone Polymers 0.000 description 2
- 229920005565 cyclic polymer Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000001907 polarising light microscopy Methods 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000010922 spray-dried dispersion Methods 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- VIESAWGOYVNHLV-UHFFFAOYSA-N 1,3-dihydropyrrol-2-one Chemical compound O=C1CC=CN1 VIESAWGOYVNHLV-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Natural products SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 229920003078 Povidone K 12 Polymers 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 231100001127 band 4 compound Toxicity 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000008867 communication pathway Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000009647 digital holographic microscopy Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 208000026934 fetal alcohol spectrum disease Diseases 0.000 description 1
- 201000007794 fetal alcohol syndrome Diseases 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 229940102465 ginger root Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001607 nephroprotective effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003214 pyranose derivatives Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- the invention pertains to compositions including dihydromyricetin (DHM) and methods for forming them, including hot melt extrusion.
- DHM dihydromyricetin
- Alcohol is a constituent of medicines, foods, and beverages that provides both beneficial and detrimental effects on human beings.
- Alcohol can refer to ethyl alcohol (ethanol), which is the common form of consumable alcohol found in alcoholic beverages, e.g., such as beer, wine, and liquor.
- ethanol ethyl alcohol
- Alcohol is rapidly absorbed from the stomach and small intestine into the bloodstream, from which it can affect several organs, including the brain, heart, pancreas, and liver.
- Alcohol can act as a depressant to the central nervous system (CNS).
- CNS central nervous system
- alcohol interferes with the brain's communication pathways, which affects brain functionality that manifests in cognitive and behavioral changes, e.g., such as a person's ability to think, focus, and move, as well as his/her mood and behavior.
- Alcohol can cause inflammation and damage to the liver, e.g., consistent heavy drinking can cause chronic liver problems.
- heavy drinking can lead to steatosis (e.g., fatty liver), infection (e.g., alcoholic hepatitis), fibrosis, and cirrhosis.
- steatosis e.g., fatty liver
- infection e.g., alcoholic hepatitis
- fibrosis fibrosis
- cirrhosis cirrhosis
- a hangover refers to an array of physical symptoms that affect a person shortly after ingesting alcohol, e.g., within hours of consumption.
- a hangover is considered to be one of the most widely experienced negative consequences of consuming ethanol.[1]
- a dihydromyricetin (DHM) formulation includes dihydromyricetin (DHM) and a matrix material.
- the matrix material can include a polymer.
- the polymer can be hydroxypropyl methyl cellulose (HPMC), cellulose ester, cellulose acrylate, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate
- the polymer can also be polyethylene oxide (PEO), a polyoxyethylene-polyoxypropylene block copolymer (a poloxamer), a polyoxyethylene alkyl ether, a polyoxyethylene castor oil, a low molecular-weight oligomer of polyethylene glycol, an ethylene glycol-vinyl glycol copolymer, a polyoxyethylene castor oil, an ethoxylated castor oil, a polyoxyl hydrogenated castor oil, a polyoxyl 40 hydrogenated castor oil, a polyethoxylated sorbitan, polyoxyethylene sorbitan monooleate, and/or combinations.
- PEO polyethylene oxide
- poloxamer a polyoxyethylene-polyoxypropylene block copolymer
- a polyoxyethylene alkyl ether a polyoxyethylene castor oil, a low molecular-weight oligomer of polyethylene glycol, an ethylene glycol-vinyl glycol copolymer, a polyoxyethylene
- the matrix material includes polyvinyl pyrrolidone (PVP). In an embodiment of the invention, the matrix material includes poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA).
- the matrix material can include a polymer.
- the polymer can be poly(methyl methacrylate) (PMMA), low molecular weight poly(methyl methacrylate), polymethacrylate, methacrylic acid copolymers, a polymethacrylate derivative, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and/or combinations.
- the polymer can also be polycaprolactam, polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-glycolic acid) (PLGA), and/or combinations.
- the matrix material can include a material, such as a wax, low melting point waxes such as carnauba wax, starch, starch derivatives, sugars, sugar alcohols, leucine, lipids, a polyol, a polyether, fructose, glucose, lactose, mannitol, trehalose, sucrose, raffinose, maltitol, lactitol, sorbitol, xylitol, erythritol, xylose, acorbose, melezitose, galactose, melibrose, isomaltose, a natural sugar extracts, malt beet sugar, corn sugar, high-fructose corn syrup, a sugar oligomers, polydextrose and dextrans with molecular weights less than 10,000 Daltons, a polyol, glycerol, sorbitol, ethylene glycol, propylene glycol, butanedi
- the DHM formulation can further include a plasticizer.
- the plasticizer can include a plasticizer, for example, triacetin, citrate ester, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and combinations.
- the plasticizer can also be low molecular weight polyols having aliphatic hydroxyls, poly(propylene glycol), low molecular weight poly(ethylene oxide) having an average molecular weight of less than about 500,000 Da, poly(ethylene glycol), D-alpha tocopheryl PEG 1000 succinate (TPGS), low molecular-weight polyethylene glycol, propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, triethylene glycol, tetraethylene glycol, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, allyl glycolate, vitamin E, and/or pressurized CO 2 .
- TPGS D-alpha tocopheryl PEG 1000 succinate
- the DHM formulation can further include a permeabilizer.
- the permeabilizer can include caprylic acid, a caprylate salt, and/or sodium caprylate.
- the permeabilizer can also include a permeabilizer such as a fatty acid, a saturated fatty acid, and/or a fatty acid complexed with a cation, such as a metal cation, a metal divalent cation, a magnesium divalent cation, a calcium divalent cation, a zinc divalent cation, an iron divalent cation, a metal trivalent cation, an iron trivalent cation, a fatty acid salt, a fatty acid metallic soap, and combinations.
- the DHM formulation can further include an antioxidant.
- the DHM formulation can further include a coactive such as glutathione, L-cysteine, N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger toot, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, and combinations.
- a coactive such as glutathione, L-cysteine, N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger toot, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, and combinations.
- the DHM formulation can further include a pH buffering agent.
- the pH buffering agent can be an acidic pH buffering agent, citric acid, a citrate salt, a sodium citrate, a potassium citrate, calcium citrate, and/or combinations.
- the DHM in the DHM formulation, is not solubilized or dissolved by an aqueous solution having a pH of at most 3.5, and the DHM is solubilized or dissolved by an aqueous solution having a pH of at least 5.5.
- the DHM comprises at least 20 wt % of the powder.
- the crystallinity of the DHM is at most 10%.
- the DHM formulation is homogeneous.
- a dosage form in an embodiment of the invention, includes the DHM formulation and an enteric coating that encapsulates the DHM formulation.
- the enteric coating can be a polymeric coating or a methacrylate copolymer coating.
- a dosage form includes the DHM formulation of in a powder form and an aqueous liquid or a gel.
- the DHM formulation can be in a powder form which is mixed with or suspended in the aqueous liquid or the gel.
- the matrix material is poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA) and the DHM comprises at least 20 wt % of the DHM formulation.
- a method for forming the dihydromyricetin includes: mixing the dihydromyricetin (DHM) and the matrix material to form a compounding mixture; processing the compounding mixture in an extruder to form an extrudate; and collecting the extrudate as the dihydromyricetin (DHM) formulation.
- the operating temperature of the extruder can be less than the melting temperature of dihydromyricetin (DHM).
- a method for reducing hangover symptoms includes: administering the dihydromyricetin (DHM) formulation to a patient suffering from hangover symptoms, so that the patient's hangover symptoms are reduced.
- DLM dihydromyricetin
- the dihydromyricetin (DHM) formulation can be used in preventing an alcohol use disorder, preventing alcoholism, treating an alcohol use disorder, treating alcoholism, or treating an alcohol overdose.
- the dihydromyricetin (DHM) formulation can be used in increasing antioxidant capacity, neuroprotection, preventing Alzheimer's disease, treating Alzheimer's disease, inhibiting inflammation, protecting the kidney, protecting the liver, preventing or treating cancer, ameliorating a metabolic disorder, preventing diabetes, treating diabetes, or treating a bacterial infection.
- An embodiment of the present invention includes a method to improve the bioavailability of the molecule dihydromyricetin (DHM) through the process known as hot melt extrusion (HME) to form a hot melt extruded formulation.
- HME hot melt extrusion
- This method can include processing by HME of a combination of materials including DHM, additional beneficial molecules (e.g., co-actives), polymeric excipients, plasticizers, and permeability-enhancing compounds (permeabilizers).
- the final form of the product may comprise powders, granules, or tablets to be used in further formulations.
- the present invention can provide a hot-melt extrusion method and resultant formulation including a beneficial amount of DHM, additional beneficial molecules, polymeric excipients, plasticizers, and permeability-enhancing compounds. Improvements in bioavailability and pharmacokinetic parameters of DHM can be associated with this formulation method.
- the formulation may be processed further in forms beyond powders, granules, and tablets for administration by various routes either by self-administration or administration by any number of routes known to a skilled artisan.
- the formulation may be well suited to oral administration routes.
- 6,488,963B1 discusses hot melt extrudable pharmaceutical formulations, which include therapeutic molecules dispersed within a high molecular weight poly(ethylene oxide) (PEO) matrix and may include plasticizers.
- PEO poly(ethylene oxide)
- Miller, et al. U.S. Pat. No. 9,504,658, U.S. Ser. No. 11/718,620
- HPMC hydroxypropyl methylcellulose
- PVA polyvinyl acetate
- No. 10/550,685 discusses a matrix composition for the delivery of APIs as oral formulations and a double-coating process including a polymer from the PEO group and a polymer from a copolymer of ethylene oxide and propylene oxide.[15] Yang, et al. (U.S. Pat. No. 8,603,514, U.S. Ser. No. 11/775,484) and Fuisz, et al. (US Pat. Applic. Pub. 2007-0281003 A1, U.S. Ser. No.
- DHM Dihydromyricetin
- DMSO dimethylsulfoxide
- DHM can be complexed with a metal, such as a divalent alkali earth metal, divalent magnesium (Mg(II), Mg +2 ), a divalent transition metal, divalent iron (Fe(II), Fe +2 ), divalent copper (Cu(II), Cu +2 ), a trivalent transition metal, or trivalent iron (Fe(III), Fe′).
- a metal such as a divalent alkali earth metal, divalent magnesium (Mg(II), Mg +2 ), a divalent transition metal, divalent iron (Fe(II), Fe +2 ), divalent copper (Cu(II), Cu +2 ), a trivalent transition metal, or trivalent iron (Fe(III), Fe′).
- a metal such as a divalent alkali earth metal, divalent magnesium (Mg(II), Mg +2 ), a divalent transition metal, divalent iron (Fe(II), Fe +2 ), divalent copper (Cu(II), Cu +2 ),
- DHM has unique physicochemical properties including low solubility, high hydroxyl functional group content, and unknown thermal stability, rendering the processing of DHM and other flavonoids under hot melt extrusion (HME) conditions difficult.
- HME hot melt extrusion
- DHM demonstrates pharmacological properties for successful medical treatment of alcohol use disorders (AUDs)[21-23]. Given limited available pharmacotherapies for AUDs and these being limited by low patient compliance, because of the adverse effects they may cause, therapies for the treatment of AUDs should be advanced, e.g., through DHM therapeutic strategies. [24]
- DHM Downlink Activated hyperplasia
- GABA A Rs GABA A receptors
- DHM and the Hovenia plant it is isolated from have shown efficacy in mitigating liver injuries[25-27], decreasing alcohol and acetaldehyde concentrations in the blood via enhancing ADH and ALDH activity[28, 29], and eliminating alcohol-induced excessive free radicals.
- DHM has been observed to have oxidative stress-mediating activity, i.e., increase antioxidant capacity for scavenging reactive oxygen species, which may result in neuroprotective, nephroprotective (kidney protecting), and hepatoprotective (liver protecting) effects, which may ameliorate, for example, the effects of hypobaric hypoxia, side effects of the chemotherapeutic agent cisplatin, and detrimental effects of ethanol.
- DHM may have a neuroprotective role in Alzheimer's and Parkinson's diseases. DHM can also inhibit inflammation. DHM can also have anticancer activity and regulate cell proliferation and apoptosis. DHM can mediate metabolism, and may be useful in ameliorating certain metabolic disorders, such as diabetes, weight gain, hyperlipidemia, and atherosclerosis. DHM exhibits antibacterial activity (Li, H. et al., “The Versatile Effects of Dihydromyricetin in Health”, Evidence Based Complementary & Alternative Medicine 2017, Art. ID 1 053617).
- a DHM formulation designed to reduce alcohol's negative effects when taken after alcohol consumption is covered under U.S. Pat. No. 9,603,830 B2 (granted on Mar. 28, 2017) and is sold in the US under the brand name Thrive+®.
- DHM oral bioavailability of less than 5% [31].
- DHM can have poor stability.
- DHM is a BCS class IV drug limited by having the properties of low solubility and low permeability. In the context of successfully commercialized drugs, DHM requires large doses for efficacy. Because DHM is a naturally occurring organic compound isolated from an herb, a DHM formulation can be classified as a food (or dietary supplement) under the Dietary Products designation.
- This invention addresses the problem of poor bioavailability and stability of DHM through the use of hot melt extrusion (HME).
- HME hot melt extrusion
- DHM can have higher supersaturation, and may exhibit increased bioavailability, be released more slowly upon ingestion, and exhibit enhanced dissolution and release kinetics, longer sustained release, higher concentrations, and improved stability with respect to low pH gastric juices and enzymes, which can cause degradation and quenching of DHM activity, than when administered in a pure form.
- the DHM HME formulation may possess improved ability to penetrate intestinal barriers, to allow DHM to reach the bloodstream more effectively and efficiently.
- Hot melt extrusion is an industrial process that can be used to create uniform polymer products such as tubes, sheets, and foams.[3-7] HME can be employed to disperse active pharmaceutical ingredients (APIs) within solid polymer matrices. [3, 5, 6] In this process, an API and polymer excipient(s) are fed into an extruder. These are then conveyed by single or double-screws down the barrel of the device while undergoing melting, mixing, dispersing, and finally cooling processes.
- APIs active pharmaceutical ingredients
- HME can be used to confer improved bioavailability and API dissolution in a final application.
- a limitation of HME is that the active compound and excipient(s) are subjected to elevated temperatures which may prompt or accelerate degradation of an API.
- hot-melt extrudable refers to a compound or formulation that may be hot-melt extruded.
- a hot-melt extrudable polymer is one that is sufficiently rigid for an intended use at standard ambient temperature and pressure, but is capable of deformation or forming a liquid or semi-liquid state under elevated heat or pressure.
- a composition for hot-melt extrusion does not include a plasticizer.
- a composition for hot-melt extrusion includes one or more plasticizers.
- the process according to the invention has been called a hot-melt extrusion, other equivalent and similar processes such as injection molding, hot dipping, melt casting, and compression molding may be used.
- the formulation may be shaped as needed according to the desired mode of administration, e.g. powders, tablets, pills, lozenges, suppositories, capsules and the like.
- the hot-melt extrusion process employed in some embodiments of the invention is conducted at an elevated temperature, i.e., the heating zone(s) of the extruder is above room temperature (about 20° C.).
- An operating temperature range should be selected that minimizes the degradation or decomposition of the therapeutic compound (e.g., DHM) during processing.
- the operating temperature range can be in the range of from about 60° C. to about 160° C. and can be set for one or more extruder heating zone(s).
- HME hot-melt extrusion
- matrix polymer(s) such as polyethylene glycol (PEG), permeability-enhancers, and/or other excipients.
- PEG polyethylene glycol
- permeability-enhancers such as polyethylene glycol (PEG)
- other excipients such as polyethylene glycol (PEG)
- Other components may be added for various embodiments of the invention.
- the mixture is then placed in the extruder hopper and passed through the heated area of the extruder at a temperature which melts or softens the matrix polymer, excipient(s), and/or plasticizer, if present, to form a matrix throughout which the therapeutic compound is dispersed.
- the molten or softened mixture then exits via a die, or other such element, at which time the mixture (now called the extrudate) begins to harden.
- the extruder used to practice the invention may be any commercially available or custom-built model equipped to handle dry feed and having a solid conveying zone, one or multiple heating zones, and an extrusion die.
- a two-stage Single Screw extruder such as that manufactured by C. W. Brabender Instruments Incorporated (NJ), is one such apparatus. It can be advantageous for the extruder to possess multiple separate temperature controllable heating zones.
- Such conditions include, by way of example, formulation composition, feed rate, operating temperature, extruder screw RPM, residence time, die configuration, heating zone length, and/or extruder torque and/or pressure.
- the extrusion conditions may be selected to produce a formulation that is a homogeneous, e.g., DHM is homogeneously dispersed in a matrix material or in a combination of matrix material(s), plasticizer(s), and/or permeabilizer(s).
- DHM homogeneous dispersed in a matrix material or in a combination of matrix material(s), plasticizer(s), and/or permeabilizer(s).
- HME can produce various forms of solid dispersions. These may include, but are not limited to, pharmaceutically-relevant dosage forms, such as powders, pellets, cylinders, tubes, granules, and flakes. These can be processed further into a desired morphology with desired surface characteristics.
- HME hot melt extrusion in the preparation of pharmaceutical dosage forms to effectively deliver DHM has several advantages.
- HME is scalable, e.g., it can be used at the lab scale, the pilot plant scale, and to mass produce large quantities of product. It allows for DHM to be formulated with a wide variety of excipient(s) and plasticizer(s) to allow for maximum effectiveness as needed for various administration routes.
- HME can be solvent free, thus reducing the need for a subsequent solvent removal step and reducing the potential for solvent-induced toxicity.[7]
- the invention includes, but is not limited to, a combination of materials including the active ingredient DHM and/or other flavonoids, additional active molecules and co-actives, permeability enhancers, excipients (including matrix materials), plasticizers, and an enteric coating.
- the HME dosage form includes dihydromyricetin (DHM) and a coactive, such as L-cysteine, N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger root, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, an antioxidant, and/or glutathione.
- DHM dihydromyricetin
- NAC N-acetyl cysteine
- Prickly Pear extract Milk Thistle, ginger root, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, an antioxidant, and/or glutathione.
- a permeability-enhancer or permeabilizer is an agent that enhances the permeation of a drug compound through the epithelial cell layer in the gastrointestinal (GI) tract and, hence, enhances the amount of drug entering the bloodstream.
- Permeability-enhancers have been reviewed by Aungst and Whitehead[32-35]. The list of agents presented by Aungst in Table I and Whitehead in Table I are incorporated into this patent in their entirety.
- permeability-enhancers are fatty acids, a saturated fatty acid, caprylic acid, a caprylate salt, sodium caprylate, a fatty acid complexed with a cation, such as a metal cation, a metal divalent cation, a magnesium (Mg(II), Mg +2 ), calcium (Ca(II), Ca +2 ), or zinc divalent cation (Zn(II), Zn +2 ), iron divalent cation (Fe(II), Fe +2 ), a metal trivalent cation, iron trivalent cation (Fe(III), Fe +3 ), a fatty acid salt, a fatty acid metallic soap, and combinations of these.
- a cation such as a metal cation, a metal divalent cation, a magnesium (Mg(II), Mg +2 ), calcium (Ca(II), Ca +2 ), or zinc divalent cation (Zn(II), Zn +
- capric acid and its salts are permeabilizers that are currently clinically approved for use in an ampicillin suppository.
- the caprates and other long-chain saturated fatty acids and their salts can be incorporated into the hot melt extrusion (HME) process.
- Their hydrophobicity can be enhanced by complexing them, for example, with divalent cations such as those of magnesium (Mg(II), Mg +2 ), calcium (Ca(II), Ca +2 ), or zinc, divalent iron, or trivalent iron.
- Permeabilizers are optional additions to the formulation. When they are used, the mass ratios of permeabilizer to DHM in the hot melt extruded formulation (extrudate) produced can range from 1:100 to 100:1.
- Excipients and matrix materials are defined as materials that aid in the formulation, stability, and/or release characteristics of the active molecule DHM.
- homopolymers, copolymers, and amphiphilic copolymers can be used as excipients and matrix materials.
- the matrix material can constitute from 0.1 wt % to 99 wt % of the combined mass of the active agent(s) and excipients by weight of the final solid form.
- the matrix material can constitute more than 20% or more than 40% of the combined mass of the active agent(s) and matrix material.
- Exemplary excipients and matrix materials include low melting point waxes such as carnauba wax, cellulose, methyl cellulose, ethyl cellulose, polyvinylpyrrolidone (PVP) and its copolymers such as polyvinylpyrrolidone-vinyl acetate (PVP-VA), poly(ethylene-co-vinyl acetate), various grades of polyethylene glycol (PEG), polyethylene oxide (PEO), cellulose esters, cellulose acrylates, cellulose derivatives, polymethacrylate, polymethacrylate derivatives, polyoxyethylene-polyoxypropylene block copolymers (also referred to as poloxamers), hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose (HPMC), HPMC derivatives, polylactic acid (PLA), poly(glycolide) (PGA), and poly(lactide-co-glycolide) (PLGA), poly(caprolactone) (PCL), starch, starch derivatives, sugars,
- excipients and matrix materials include polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polycaprolactam, hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate (HPMCAT), hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate (CAS),
- the excipients and matrix materials can include amphiphilic block copolymers, for example, polystyrene-block-polyethylene glycol (PS-b-PEG), polylactic acid-block-polyethylene glycol (PLA-b-PEG), and poly(lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-b-PEG).
- PS-b-PEG polystyrene-block-polyethylene glycol
- PLA-b-PEG polylactic acid-block-polyethylene glycol
- PLGA-b-PEG poly(lactic-co-glycolic acid)-block-polyethylene glycol
- excipients and matrix materials examples include derivatives of the above, copolymers of the above, and combinations of the above.
- the matrix material includes components with a molecular weight of less than 1,000,000 Daltons (Da), less than 100,000 Daltons, less than 10,000 Daltons, less than 5000 Daltons, or less than 2000 Daltons.
- the matrix material can include a polymer.
- a polymer is formed of several monomer units bound to each other.
- a polymer can be a linear polymer, a branched polymer, or a cyclic polymer.
- a set of monomers can be bound to each other to form a ring.
- a noncyclic polymer there is no set of monomers that are bound to each other to form a ring (although atoms within a given monomer unit of the polymer still may be in a ring structure, e.g., a cyclopentyl, furan, furanose, cyclohexyl, pyran, pyranose, benzene, or saccharide structure).
- cyclodextrin is a cyclic polysaccharide.
- cellulose is a linear polysaccharide formed of several hundred to many thousands of D-glucose monomers.
- Gum arabic includes arabinogalactan, formed of arabinose and galactose monomers.
- BASF Povidones, copovidones, methacrylic acid copolymers, ethylene glycol-vinyl glycol copolymers, Poloxamer 407, Poloxamer 188, poly ethylene glycols, polyoxyl 40 hydrogenated castor oils, and polymeric derivatives of vitamin E marketed by BASF under trade names SOLUPLUS, KOLLIDON VA 64, KOLLIDON 12 PF, KOLLIDON 17 PF, KOLLIDON 30, KOLLIDON 90 F, KOLLIDON SR, KOLLICOAT MAE 100P, KOLLICOAT IR, KOLLICOAT PROTECT, KOLLIPHOR P 407, KOLLIPHOR P407 MICRO, KOLLIPHOR P188, KOLLIPHOR P188 MICRO, KOLLISOLV PEG, KOLLIPHOR RH 40, KOLLIPHOR TPGS.
- SOLUPLUS KOLLIDON VA 64, KOLLIDON 12 PF,
- the Dow Chemical Company Polymers with trade names METHOCEL, ETHOCEL, POLYOX, and AFFINISOL marketed by the Dow Chemical Company.
- Evonik Corporation Polymers with trade names EUDRAGIT® (methacrylates) and RESOMER, marketed by Evonik Corporation.
- Ashland Polymers with trade names AquaSolve hypromellose acetate succinate, Aqualon ethylcellulose, Aqualon sodium carboxymethylcellulose, Aquarius control film coating systems, Aquarius prime film coating systems, Aquarius protect film coating systems, Aquarius film coating systems, Aquarius preferred film coating systems, Benecel methylcellulose and hypromellose, Blanose sodium carboxymethylcellulose, CAVAMAX native cyclodextrins, Cavitron cyclodextrin, CAVASOL cyclodextrin, Klucel hydroxypropylcellulose, Natrosol hydroxyethylcellulose, Pharmasolve N-methyl-2-pyrrolidone, Plasdone S-630 copovidone, Plasdone povidone, and Polyplasdone crospovidone (cross linked polyvinyl N-pyrrolidone) marketed by Ashland Global Holdings Inc.
- the polymer matrix material can have a glass transition temperature (Tg) of at least 50° C., 60° C., 70° C., 80° C., 90° C., 100° C., 110° C., 115° C., 120° C., 125° C., 130° C., 150° C., 175° C., 200° C., or 250° C.
- Tg glass transition temperature
- HPMCAS hydroxypropyl methyl cellulose acetate succinate
- Tg glass transition temperature of about 120° C.
- the polymer matrix material may be selected to adjust the formulation's release profile, e.g., to adjust the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM.
- API active pharmaceutical ingredient
- polymers such as one or more of those listed above, may also be incorporated as enteric coatings which coat a final tablet form of a DHM hot-melt extruded (HME) formulation and provide additional stability or sustained release benefits.
- HME hot-melt extruded
- including an enteric coating in the formulation may alter the formulation's release profile, e.g., may alter the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM.
- the enteric coating may be a methacrylate copolymer coating.
- plasticizer includes compounds capable of plasticizing the polymeric excipients, including the polymer matrix material, used.
- the plasticizer may lower the glass transition temperature or softening point of the excipient(s) in order to allow for lower processing temperature, extruder torque, and pressure during the hot-melt extrusion (HME) process.
- Plasticizers such as PEG and low molecular weight PEO, can broaden the average molecular weight of the polymeric excipients used, thereby lowering the glass transition temperature or softening point of the composition being extruded.
- Plasticizers can reduce the viscosity of a polymer melt, thereby allowing for lower processing temperature and extruder torque during hot-melt extrusion.
- a plasticizer may impart advantageous physical properties to the extruded formulation.
- the term “low molecular weight PEO” means poly(ethylene oxide) homopolymer having an average molecular weight less than about 500,000.
- the composition that undergoes hot melt extrusion (HME) and the extruded formulation do not include a plasticizer. In an embodiment according to the invention, the composition that undergoes hot melt extrusion (HME) and the extruded formulation include a plasticizer.
- Including a plasticizer in the formulation may alter the formulation's release profile, e.g., may alter the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM.
- API active pharmaceutical ingredient
- Increasing the amount of plasticizer in the formulation may increase the release rate of the therapeutic compound (API, e.g., DHM).
- a combination of plasticizers may be used in the composition to be extruded and the extruded formulation.
- Plasticizers that may be used in an embodiment of the invention include, by way of example and without limitation, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene oxide) (e.g., having an average molecular weight of less than about 500,000 Da), and poly(ethylene glycol).
- low molecular weight polymers oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene oxide) (e.g., having an average molecular weight of less than about 500,000 Da), and poly(ethylene glycol).
- Plasticizers that may be used in an embodiment of the invention include, but are not limited to triacetin, citrate ester, vitamin E, D-alpha tocopheryl PEG 1000 succinate (TPGS), molecular surfactants, low molecular-weight polyethylene glycol, pressurized CO 2 , propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene, a glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and allyl glycolate.
- plasticizers include derivatives of the above, copolymers of the above, and combinations of the above.
- the amount of plasticizer used in the formulation may affect the formulation's properties.
- the amount of plasticizer selected for use in the composition for HME and the formulation produced can will depend upon the plasticizers composition, physical properties, effect upon the excipient(s), interaction with other components of the formulation, ability to solubilize the therapeutic compound, and/or other factors.
- DHM constitutes at least 0.1 wt %, 1 wt %, 2 wt %, 3 wt %, 5 wt %, 7 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, 35 wt %, 40 wt %, 50 wt %, 55 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 98 wt %, or 99 wt % of the HME formulation, relative to the total mass of the formulation, including all other excipients and matrix materials.
- the concentration of all other components, and particularly excipients and matrix materials, in the formulation may range from 0.001 wt % to 0.01 wt %, or from 0.01 wt % to 0.1 wt %, or from 0.1 wt % to 1 wt %, or from 1 wt % to 10 wt %, or from 10 wt % to 99.9 wt %, depending on the desired release profile, the pharmacological activity and toxicity of the therapeutic compound, such as DHM and any coactive, and other such considerations.
- compositions of embodiments of the present invention are useful and suitable for delivery in animals and humans and may be administered by a variety of methods. Such methods include, by way of example and without limitation: oral, nasal, buccal, rectal, ophthalmic, otic, urethral, vaginal, or sublingual dosage administration. Such methods of administration and others contemplated within the scope of the present invention are known to the skilled artisan.
- In vivo stability of the present formulation may vary according to the physiological environment to which it is exposed and the matrix material, excipients, and plasticizer used. Therefore, the necessity for or frequency of readministration may be different for various formulations.
- the formulation of the present invention may be provided in a variety of ways, for example, powder, tablet, and capsule dosage forms. Additional components that would not significantly prohibit the hot-melt extrusion (HME) process may be added to the formulation prior to hot-melt extrusion. That is, such additional components should still allow for formulation using the hot-melt extrusion process.
- HME hot-melt extrusion
- the formulation may be in the form of a gel cap, caplet, tablet, capsule, suspension, or powder.
- the formulation may be in the form of a mixture with or suspension in, e.g., a DHM-containing powder according to an embodiment of the invention mixed with or suspended in, a consumable (edible) liquid (e.g., an aqueous liquid, such as water), such as a drink or liquid concentrate.
- the formulation may be in the form of a mixture with or suspension in, e.g., a DHM-containing powder according to an embodiment of the invention mixed with or suspended in, an edible gel.
- the formulation may be in the form of a suppository, ointment, enema, tablet, or cream for release of compound into the intestines, sigmoid flexure, and/or rectum.
- the compounds can be combined with conventional carriers, for example, one or more of the following: binders, such as acacia, corn starch, or gelatin; disintegrating agents, such as corn starch, guar gum, potato starch, or alginic acid; lubricants, such as stearic acid or magnesium stearate; and inert fillers, such as lactose, sucrose, or corn starch.
- binders such as acacia, corn starch, or gelatin
- disintegrating agents such as corn starch, guar gum, potato starch, or alginic acid
- lubricants such as stearic acid or magnesium stearate
- inert fillers such as lactose, sucrose, or corn starch.
- either one or a combination of long-acting, sustained-release, controlled-release, and/or or slow-release dosage forms may be used in the present invention. This may be desirable, if continuous exposure of an animal or a human to the active ingredient(s) (e.g., DHM) is the desired outcome.
- the polymers and formulations useful in this case can include derivatized cellulosic polymers of the type described in the Dow Chemical Company Technical Bulletin “Using Dow Excipients for Controlled Release of Drugs in Hydrophilic Matrix Systems”, 2006 and marketed under the trade name METHOCEL (methylcellulose and hydroxypropyl methylcellulose (HPMC) polymers).
- METHOCEL methylcellulose and hydroxypropyl methylcellulose (HPMC) polymers
- Increased bioavailability can be achieved using HME processing by tuning the interactions between the drug (e.g., DHM) and the HME polymer.
- the drug e.g., DHM
- the drug can be substantially soluble in the molten polymer phase, which can include one or more excipient(s) and/or plasticizers, such that upon cooling and solidification, that drug is prevented from substantially crystallizing.
- Capturing the drug (e.g., DHM) in an amorphous, or non-crystalline-associated state (which can be a high-energy state), can result in a higher dissolution level or a supersaturation level, when dissolved in vitro or in vivo. Thermodynamic reasons for this increase in solubility have been discussed by Hu, Johnson & Williams.[36]
- the crystallinity of the DHM in the hot-melt extruded (HME) formulation can be qualitatively assessed or quantitatively measured by techniques, such as polarized light microscopy (PLM), differential scanning calorimetry (DCS), and powder X-ray diffraction (P-XRD).
- the DHM in the hot-melt extruded (HME) formulation can have a crystallinity of less than or equal to 90%, 80%, 60%, 50%, 40%, 30%, 20%, 25%, 20%, 15%, 10%, 7%, 5%, 3%, 2%, or 1%.
- the DHM in the hot melt extruded formulation (extrudate) can be amorphous.
- the DHM in the hot melt extrusion formulation does not dissolve in and/or is not solubilized by an aqueous solution having a pH of at most (i.e., less than or equal to) 4.8, 4.5, 4, 3.5, 3.2, 3, 2.7, 2.5, 2.3, 2, 1.8, 1.5, or 1.
- the chyme that is expelled by the stomach, through the pyloric valve has a pH of approximately 2. Gastric juices lead to material in the stomach having a pH in the range of from 1.5 to 3.5, and this low pH in the stomach and the enzymes active in the stomach at this low pH may result in degradation of DHM and quenching of DHM activity.
- the DHM in the hot-melt extruded (HME) formulation dissolves in and/or is solubilized by water (pH of 7) and/or an aqueous solution having a pH of at least (i.e., greater than or equal to) 5, 5.3, 5.5, 5.8, 6, 6.2, 6.5, 6.7, 7, 7.2, or 7.5.
- Bile released into the duodenum and/or pancreatic secretions of sodium bicarbonate increase the pH of the chyme.
- the pH of chyme and material in the intestine (bowel) can range from 5.5 to 7, for example, can be 7.
- the dissolution and/or solubilization of the DHM in the hot melt extruded formulation in the intestine, for example, the small intestine can result in the DHM being absorbed by the wall of the intestine, for example, the wall of the small intestine, and into the blood.
- HPMCAS hydroxypropyl methyl cellulose acetate succinate
- HPMCAS hot-melt extruded
- DHM can retain the DHM at an acidic (low) pH, e.g., a pH of 3.5 or less, but release the DHM at a neutral or alkaline (high) pH, e.g., a pH of 7 or greater.
- a pH buffering agent can be included in such a hot-melt extruded (HME) formulation.
- an acidic component in such a hot-melt extruded (HME) formulation such as an acidic pH buffering agent (i.e., a buffering agent that maintains an acidic pH, a pH of less than 7), e.g., citric acid or a citrate salt (e.g., a sodium citrate, a potassium citrate, calcium citrate, and/or combinations), can stabilize an aqueous solution formed with the hot-melt extruded (HME) formulation, so that the DHM is not released into the aqueous solution or so that the release of the DHM into the aqueous solution is delayed.
- an acidic pH buffering agent i.e., a buffering agent that maintains an acidic pH, a pH of less than 7
- citric acid or a citrate salt e.g., a sodium citrate, a potassium citrate, calcium citrate, and/or combinations
- the polymer matrix material can be selected, so that it is moderately soluble (e.g., from 0.01 g/100 mL to 3 g/100 mL, or from 0.1 g/100 mL to 1 g/100 mL) in water. Moderate solubility in water allows the polymer matrix material to dissolve in the body of an organism and release the DHM.
- Simulated gastric fluid (FaSSGF) and intestinal fluids (FaSSIF and FeSSIF) are prepared according to the manufacturer's instructions. Dissolution tests are performed with hot-melt extruded (HME) DHM-containing powders or tablets with the appropriate controls.
- HME hot-melt extruded
- DHM-containing hot melt extruded (HME) powder samples are suspended in prewarmed FaSSGF (37° C.) to achieve a drug (DHM) concentration of roughly 10-100 ⁇ the previously determined equilibrium solubility in the FaSSGF fluid (e.g., 75 ⁇ g/mL) by pipetting up and down vigorously multiple times.
- the samples are incubated for the duration of the study (e.g., 30 min) at 37° C. (NesLab RTE-111 bath circulator, Thermo Fisher Scientific, Waltham, Mass.) without agitation to mimic physiological gastric conditions and transition time in the stomach. Aliquots can be taken, for example, at 1, 5, 10, 15, 30, 60, 120, and 360 min.
- each aliquot can be centrifuged at 28000 g for 5 min to pellet suspended particles.
- the supernatant is frozen and lyophilized; the remaining solids are reconstituted in, for example, 2:8 THF (tetrahydrofuran):acetonitrile to dissolve DHM and precipitate out lipids and salts from the release media.
- the samples are then diluted as appropriate to fall within the detection range and analyzed by high-performance liquid chromatography (HPLC), with the mobile phase as 80:20 H 2 O:acetonitrile (each with 0.05% trifluoroacetic acid), and with detection with UV-Vis at 290 nm.
- the concentration of DHM is then calculated based on a calibration curve.
- DHM-containing hot melt extruded (HME) powder samples are suspended in prewarmed (37° C.) Fed State Simulated Intestinal Fluid (FeSSIF) or Fasted State Simulated Intestinal Fluid (FaSSIF) to achieve a drug (DHM) concentration of roughly 10-100 ⁇ the previously determined equilibrium solubility in the FeSSIF or FaSSIF fluid by pipetting up and down vigorously multiple times.
- FeSSIF Fed State Simulated Intestinal Fluid
- FaSSIF Fasted State Simulated Intestinal Fluid
- FaSSIF is a biorelevant intestinal media representing the fasted state intestinal fluid
- FeSSIF is another biorelevant intestinal media representing the fed state intestine fluid.
- FaSSIF and FeSSIF have different compositions.
- components of FaSSIF include 3 mM taurocholate, 0.75 mM phospholipids, 148 mM sodium, 106 mM chloride, and 29 mM phosphate
- components of FeSSIF include 15 mM taurocholate, 3.75 mM phospholipids, 319 mM sodium, 203 mM chloride, and 144 mM acetic acid.
- the presence of food changes the pH and composition of fats and surfactants in the intestinal fluid.
- FaSSIF has a higher pH (6.5) than FeSSIF (5.0) and has lower levels of fat.
- the intestine can be the site of absorption for oral dosage forms, thus understanding the solubility of a drug or active ingredient in the intestinal fluid can be important.
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 15 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 15 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 30 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 30 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 60 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 60 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 120 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 120 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 360 minutes over that of pure DHM.
- HME hot-melt extruded
- the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 360 minutes over that of pure DHM.
- HME hot-melt extruded
- DHM-containing samples e.g., hot-melt extruded (HME) formulations in an embodiment of the present invention
- HME hot-melt extruded
- an animal e.g., a rat or a mouse
- the plasma concentration of DHM can be determined, for example, using a Waters Acquity ultra performance liquid chromatography system equipped with an electrospray ionization mass spectrometry system (Waters, Milford, Mass.), in accordance with a previous report [38], or an equivalent analytical analysis system.
- An animal dosed with a hot melt extrusion formulation containing DHM according to the present invention can show increased blood maximum concentrations, relative to dosing with pure DHM powder, of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, 250%.
- the area under the curve (AUC) for 24 hours can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, 250% over the value associated with dosing with pure DHM powder.
- a dihydromyricetin (DHM) formulation comprising:
- DHM is dispersed within the matrix material
- the matrix material is a solid.
- Aspect 2 The DHM formulation of Aspect 1, wherein the matrix material comprises a polymeric matrix material.
- Aspect 3 The DHM formulation of any one of Aspects 1 through 2, wherein the matrix material comprises cellulose and/or a cellulose derivative.
- Aspect 4. The DHM formulation of any one of Aspects 1 through 3, wherein the matrix material comprises hydroxypropyl methyl cellulose (HPMC).
- HPMC hydroxypropyl methyl cellulose
- the matrix material comprises a material selected from the group consisting of cellulose ester, cellulose acrylate, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate (HPM
- Aspect 6 The DHM formulation of any one of Aspects 1 through 5, wherein the matrix material comprises polyethylene oxide (PEO).
- Aspect 7. The DHM formulation of any one of Aspects 1 through 6, wherein the matrix material comprises a material selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers (also referred to as poloxamers), polyoxyethylene alkyl ethers, polyoxyethylene castor oils, a low molecular-weight oligomer of polyethylene glycol, an ethylene glycol-vinyl glycol copolymer, polyoxyethylene castor oils, ethoxylated castor oil, polyoxyl hydrogenated castor oil,polyoxyl 40 hydrogenated castor oil, polyethoxylated sorbitan, polyoxyethylene sorbitan monooleate, and combinations.
- polyoxyethylene-polyoxypropylene block copolymers also referred to as poloxamers
- polyoxyethylene alkyl ethers polyoxyethylene castor oils
- Aspect 8 The DHM formulation of any one of Aspects 1 through 7, wherein the matrix material comprises a material selected from the group consisting of polyvinyl pyrrolidone (PVP) and poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA).
- PVP polyvinyl pyrrolidone
- PVP-VA poly(vinyl pyrrolidone-co-vinyl acetate)
- the matrix material comprises a material selected from the group consisting of poly(methyl methacrylate) (PMMA), low molecular weight poly(methyl methacrylate), polymethacrylate, methacrylic acid copolymers, polymethacrylate derivatives, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and combinations.
- PMMA poly(methyl methacrylate)
- low molecular weight poly(methyl methacrylate) polymethacrylate
- methacrylic acid copolymers polymethacrylate derivatives
- poly(methacrylic acid-co-methyl methacrylate) 1:1 poly(methacrylic acid-co-methyl methacrylate) 1:2
- poly(methacrylic acid-co-ethyl acrylate) 1:1 and combinations.
- the matrix material comprises a material selected from the group consisting of polycaprolactam, polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-glycolic acid) (PLGA), and combinations.
- PCL polycaprolactam
- PLA polycaprolactone
- PGA polyglycolic acid
- PLGA poly(lactic-glycolic acid)
- the matrix material comprises a material selected from the group consisting of a wax, low melting point waxes such as carnauba wax, starch, starch derivatives, sugars, sugar alcohols, leucine, lipids, a polyol, a polyether, fructose, glucose, lactose, mannitol, trehalose, sucrose, raffinose, maltitol, lactitol, sorbitol, xylitol, erythritol, xylose, acorbose, melezitose, galactose, melibrose, isomaltose, a natural sugar extracts, malt beet sugar, corn sugar, high-fructose corn syrup, a sugar oligomers, polydextrose and dextrans with molecular weights less than 10,000 Daltons, a polyol, glycerol, sorbito
- Aspect 12 The DHM formulation of any one of Aspects 1 through 11, further comprising a plasticizer.
- Aspect 13 The DHM formulation of Aspect 12, wherein the plasticizer comprises a plasticizer selected from the group consisting of low molecular weight polyols having aliphatic hydroxyls, poly(propylene glycol), low molecular weight poly(ethylene oxide) (e.g., having an average molecular weight of less than about 500,000 Da), and poly(ethylene glycol), D-alpha tocopheryl PEG 1000 succinate (TPGS), low molecular-weight polyethylene glycol, propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate,
- Aspect 14 The DHM formulation of any one of Aspects 12 and 13, wherein the plasticizer comprises a plasticizer selected from the group consisting of triacetin, vitamin E, pressurized CO 2 , citrate ester, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and combinations.
- the plasticizer comprises a plasticizer selected from the group consisting of triacetin, vitamin E, pressurized CO 2 , citrate ester, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and combinations.
- Aspect 16 The DHM formulation of any one of Aspects 1 through 15, further comprising a permeabilizer.
- Aspect 17 The DHM formulation of Aspect 16, wherein the permeabilizer comprises caprylic acid, a caprylate salt, and/or sodium caprylate.
- Aspect 19 The DHM formulation of any one of Aspects 1 through 18, further comprising a coactive.
- Aspect 20 The DHM formulation of any one of Aspects 1 through 18, further comprising a coactive.
- the DHM formulation of Aspect 19, wherein the coactive comprises an antioxidant.
- Aspect 21 The DHM formulation of any one of Aspects 19 and 20, wherein the coactive is glutathione.
- Aspect 22. The DHM formulation of any one of Aspects 19 through 21, wherein the coactive is L-cysteine.
- Aspect 23. The DHM formulation of any one of Aspects 19 through 22, wherein the coactive is selected from the group consisting of N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger toot, vitamin B, vitamin C, vitamin E, and combinations.
- Aspect 24 The DHM formulation of any one of Aspects 19 through 23, wherein the coactive comprises an electrolyte and/or a sugar.
- Aspect 28. The DHM formulation of any one of Aspects 1 through 27, wherein the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 3.5.
- Aspect 30 The DHM formulation of any one of Aspects 1 through 28, wherein the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 2.
- Aspect 30 The DHM formulation of any one of Aspects 1 through 29, wherein the DHM is solubilized or dissolved by an aqueous solution having a pH of at least 5.5.
- Aspect 31 The DHM formulation of any one of Aspects 1 through 29, wherein the DHM is solubilized or dissolved by water or an aqueous solution having a pH of at least 7.
- Aspect 32 The DHM formulation of any one of Aspects 1 through 31, wherein the DHM comprises at least 5 wt % of the powder.
- Aspect 33 The DHM formulation of any one of Aspects 1 through 28, wherein the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 2.
- Aspect 31 The DHM formulation of any one of Aspects 1 through 29, wherein the DHM is
- Aspect 39 The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 5%.
- Aspect 39 The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 2%.
- Aspect 40 The DHM formulation of any one of Aspects 1 through 35, wherein the DHM is amorphous.
- Aspect 41 The DHM formulation of any one of Aspects 1 through 40, wherein the DHM formulation is homogeneous and/or molecularly dispersed.
- Aspect 42 A dosage form, comprising
- Aspect 43 The dosage form of Aspect 42, wherein the enteric coating is a polymeric coating.
- Aspect 44 The dosage form of Aspect 42, wherein the enteric coating is a methacrylate copolymer coating.
- Aspect 45 The dosage form of any one of Aspects 42 through 44, wherein the dosage form is a capsule, tablet, or pill.
- Aspect 46 A dosage form, comprising
- a dosage form comprising
- Aspect 48 The DHM formulation of Aspect 1,
- the matrix material is polyethylene oxide (PEO), and
- the DHM comprises at least 5 wt % of the DHM formulation.
- Aspect 49 The DHM formulation of Aspect 1,
- the matrix material is hydroxypropyl methylcellulose (HPMC)
- the DHM comprises at least 5 wt % of the DHM formulation.
- Aspect 51 The method of Aspect 50, further comprising grinding the extrudate into a powder.
- Aspect 52 The method of Aspect 51, further comprising filling the powder into a capsule or pressing the powder into a tablet.
- Aspect 53 The method of Aspect 50, comprising,
- DMD dihydromyricetin
- PEO polyethylene oxide
- Aspect 54 The method of Aspect 50, comprising,
- DMM dihydromyricetin
- HPMC hydroxypropyl methylcellulose
- Aspect 55 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use as a medicament.
- Aspect 56 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in reducing hangover symptoms.
- Aspect 57 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing an alcohol use disorder.
- Aspect 58 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing an alcohol use disorder.
- Aspect 60 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating alcoholism.
- Aspect 62. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in increasing antioxidant capacity.
- Aspect 63 The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in neuroprotection.
- Aspect 71. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing diabetes.
- Aspect 75 Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for preventing an alcohol use disorder, preventing alcoholism, treating an alcohol use disorder, treating alcoholism, and/or treating an alcohol overdose.
- Aspect 76 Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for neuroprotection, preventing Alzheimer's disease, and/or treating Alzheimer's disease.
- Aspect 77 Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for ameliorating a metabolic disorder, preventing diabetes, and/or treating diabetes.
- Aspect 78 Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for ameliorating a metabolic disorder, preventing diabetes, and/or treating diabetes.
- DHM dihydromyricetin
- Aspect 79 The DHM formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49, so that mixing of the DHM formulation with a solvent results in a concentration of DHM dissolved in the solvent that is at least 20%, 50%, 70%, 100%, 200%, 400%, or 900% greater than the equilibrium concentration of crystalline DHM dissolved in the solvent.
- Aspect 80 The DHM formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49, so that mixing of the DHM formulation with a solvent results in a concentration of DHM dissolved in the solvent that is at least 20%, 50%, 70%, 100%, 200%, 400%, or 900% greater than the equilibrium concentration of crystalline DHM dissolved in the solvent.
- Aspect 81. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0.
- Aspect 82. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM.
- the DHM formulation of Aspect 79 wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM and a surfactant at a concentration of from 0.01 wt % to 2 wt %.
- Aspect 84 The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM and a nonionic surfactant at a concentration of from 0.05 wt % to 1.5 wt %.
- Aspect 85 The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM and a nonionic surfactant at a concentration of from 0.05 wt % to 1.5 wt %.
- Example 1 Preparation of a DHM—Poly(Ethylene Oxide) Hot-Melt Extruded (HME) Formulation
- An amount of dihydromyricetin (DHM) sufficient to provide an effective amount of the formulation may be mixed with a known amount of polyethylene oxide (PEO) polymer.
- the weight ratio of DHM to polymer may be about 5:95.
- the mixture may then be placed into an extruder hopper.
- the extruder used should include a solids-conveying mechanism (e.g., a screw or twin screws) that extends from the hopper through a heating zone to the extrusion die.
- the mixture is passed through the heated extruder at a temperature range which may be from about 100° C. to about 140° C., as set by the temperature setting of the extruder heating zone, so that melting or softening of the PEO occurs.
- the extrudate (PEO/DHM) may be chopped to the desired length.
- the extrudate may then be, for example, ground to a powder and filled into a capsule or pressed into a tablet.
- An amount of dihydromyricetin (DHM) sufficient to provide an effective amount of the formulation may be mixed with a known amount of cellulose-derived AFFINISOLTM HPMC HME hydroxypropyl methylcellulose (HPMC) polymer of low to medium molecular weight.
- HPMC cellulose-derived AFFINISOLTM HPMC HME hydroxypropyl methylcellulose
- the weight ratio of DHM to polymer may be about 5:95.
- the mixture may then be placed into an extruder hopper.
- the extruder to be used should include a solids-conveying mechanism (e.g., a screw or twin screws) that extends from the hopper through a heating zone to the extrusion die.
- the mixture is passed through the heated extruder at a temperature range which may be from about 100° C. to about 155° C., as set by the temperature setting of the extruder heating zone, so that the polymer is sufficiently melted or softened.
- the extrudate HPMC/DHM
- the extrudate may then be, for example, ground to a powder, filled into a capsule, or pressed into a tablet.
- Example 3 Preparation of a DHM—Poly(Vinylpyrrolidone-Co-Vinyl Acetate) (PVP-VA) Hot-Melt Extruded (HME) Formulation
- DHM dihydromyricetin
- PVP-VA poly(vinylpyrrolidone-co-vinyl acetate)
- BASF Kollidon VA 64 which is an amorphous copolymer having 60% vinylpyrrolidone and 40% vinyl acetate, a molecular weight of about 45,000 g/mol, and a glass-transition temperature (Tg) measured to be 109° C.
- Tg glass-transition temperature
- a HAAKE Mini-Lab II extruder having a chamber volume of 7 cm 3 , counter-rotating twin screws, and an internal recirculation channel was used. Approximately 5 g of the physical mixture of DHM and PVP-VA was loaded into the extruder. The mixture was passed through the heated extruder at about 160° C., with the extruder operated at 30-50 rpm. Approximately 5 min loading time, 5 min recirculation time, and 5 min unloading time were used. The extrudate was then collected as the dihydromyricetin (DHM) formulation.
- DHM dihydromyricetin
- the drug (DHM) loading in the extrudate was 20 wt %, i.e., the weight ratio of DHM:PVP-VA was 20:80.
- the weight ratio of DHM to PVP-VA may be about 5:95, 10:90, 30:70, 40:60, 50:50, 60:40, or 80:20.
- the DHM/PVP-VA (20/80) extrudate from this hot melt extrusion (HME) was darker brown and uniform in color and somewhat opaque, indicating that the DHM was uniformly dispersed in the extrudate.
- the glass-transition temperature (Tg) of this DHM/PVP-VA (20/80) HME extrudate was 126° C.
- the PVP-VA in the DHM/PVP-VA (20/80) extrudate was amorphous.
- extruded PVP-VA polymer (without DHM) was lighter brown in color and more translucent.
- the Tg of this extruded PVP-VA polymer was measured to be 108° C., the same as the bulk PVP-VA (BASF Kollidon VA64) copolymer, indicating that extrusion did not change the Tg of the polymer.
- the PVP-VA in the extrudate was amorphous.
- the melting temperature (point) Tm of DHM is approximately 240° C.-256° C., for example, about 240° C.
- the operating temperature of the extruder about 160° C. was less than the melting temperature of the DHM.
- the DHM was thought to have dissolved into the molten PVP-VA polymer in the extruder.
- the Tg of DHM is inferred to be less than 120° C. That is, a spray dried dispersion (SDD) of DHM and hydroxypropyl methylcellulose acetate succinate (HPMCAS) exhibited an intermediate Tg less than the Tg of HPMCAS ( ⁇ 120° C.), so that the Tg of DHM is inferred to be less than the Tg of HPMCAS.
- SDD spray dried dispersion
- HPMCAS hydroxypropyl methylcellulose acetate succinate
- the Tg of the DHM/PVP-VA (20/80) HME extrudate (126° C.) was greater than the Tg of the DHM (less than 120° C.) and was greater than the Tg of the PVP-VA matrix (about 108° C.).
- In vitro release data may be obtained to allow comparison of the concentration of DHM in a liquid yielded by starting crystalline DHM material with the concentration of DHM in a liquid yielded by a DHM—matrix HME formulation over a time period, such as a 6-hour time period with sampling timepoints at 1, 5, 10, 15, 30, 60, 120, and 360 minutes.
- the release study may be performed in fed state simulated intestinal fluid (FeSSIF), with or without 1% v/v Tween 20 (Polysorbate 20) having been added.
- the fluid may be maintained at a temperature of 37° C. for the duration of the experiment.
- the starting crystalline DHM material or the HME formulation may be loaded into a separate volume of prepared FeSSIF fluid at a concentration substantially greater than the equilibrium solubility of DHM in FeSSIF (140 ⁇ g/mL).
- the starting crystalline DHM material or the HME formulation may be loaded into the prepared FeSSIF fluid at a DHM concentration of 1400 ⁇ g/mL, 10 times the equilibrium solubility of crystalline DHM in FeSSIF, or at a DHM concentration of 7 mg/mL, 50 times the equilibrium solubility of DHM in FeSSIF.
- the excess DHM loaded into the release media enables detection and quantitation of potentially supersaturated dissolved DHM concentrations that a given formulation may provide.
- the HME formulation may be found to produce a supersaturated DHM concentration that is greater than that of the crystalline DHM.
- Such release studies may establish that the HME formulation will release a concentration of dissolved DHM into a patient's intestine that is greater than the concentration of dissolved DHM released by crystalline DHM.
- the greater concentration of dissolved DHM released into the patient's intestine may result in the HME formulation promoting uptake of DHM into the overall system (body) of the patient that is greater than the DHM uptake when crystalline DHM is administered, by way of an increased concentration driving force of the DHM across the membrane of the intestine.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application claims the benefit of U.S. Provisional Application No. 62/767,208, filed Nov. 14, 2018, which is hereby incorporated by reference in its entirety.
- The invention pertains to compositions including dihydromyricetin (DHM) and methods for forming them, including hot melt extrusion.
- Alcohol is a constituent of medicines, foods, and beverages that provides both beneficial and detrimental effects on human beings. Alcohol can refer to ethyl alcohol (ethanol), which is the common form of consumable alcohol found in alcoholic beverages, e.g., such as beer, wine, and liquor. During consumption, alcohol is rapidly absorbed from the stomach and small intestine into the bloodstream, from which it can affect several organs, including the brain, heart, pancreas, and liver. Alcohol can act as a depressant to the central nervous system (CNS). For example, alcohol interferes with the brain's communication pathways, which affects brain functionality that manifests in cognitive and behavioral changes, e.g., such as a person's ability to think, focus, and move, as well as his/her mood and behavior. Alcohol can cause inflammation and damage to the liver, e.g., consistent heavy drinking can cause chronic liver problems. For example, heavy drinking can lead to steatosis (e.g., fatty liver), infection (e.g., alcoholic hepatitis), fibrosis, and cirrhosis. More commonly, even a single instance of light to moderate to heavy alcohol consumption can result in what is commonly known as an ‘alcohol hangover’. A hangover refers to an array of physical symptoms that affect a person shortly after ingesting alcohol, e.g., within hours of consumption. The symptoms of a hangover include, for example, one or more of thirst, fatigue and/or weakness, headache and/or muscle aches, dizziness/faintness, loss of appetite, poor and/or decreased sleep, nausea and/or stomach pain (e.g., which can include vomiting), and elevated heart rate. A hangover is considered to be one of the most widely experienced negative consequences of consuming ethanol.[1]
- In an embodiment of the invention, a dihydromyricetin (DHM) formulation includes dihydromyricetin (DHM) and a matrix material. The matrix material can include a polymer. For example, the polymer can be hydroxypropyl methyl cellulose (HPMC), cellulose ester, cellulose acrylate, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate (HPMCAT), hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate (CAS), methyl cellulose acetate succinate (MCAS), carboxymethylcellulose, carboxymethylcellulose salt, sodium carboxymethylcellulose, a cellulose polymer, and/or combinations.
- The polymer can also be polyethylene oxide (PEO), a polyoxyethylene-polyoxypropylene block copolymer (a poloxamer), a polyoxyethylene alkyl ether, a polyoxyethylene castor oil, a low molecular-weight oligomer of polyethylene glycol, an ethylene glycol-vinyl glycol copolymer, a polyoxyethylene castor oil, an ethoxylated castor oil, a polyoxyl hydrogenated castor oil, a polyoxyl 40 hydrogenated castor oil, a polyethoxylated sorbitan, polyoxyethylene sorbitan monooleate, and/or combinations.
- In an embodiment of the invention, the matrix material includes polyvinyl pyrrolidone (PVP). In an embodiment of the invention, the matrix material includes poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA).
- The matrix material can include a polymer. The polymer can be poly(methyl methacrylate) (PMMA), low molecular weight poly(methyl methacrylate), polymethacrylate, methacrylic acid copolymers, a polymethacrylate derivative, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and/or combinations. The polymer can also be polycaprolactam, polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-glycolic acid) (PLGA), and/or combinations.
- The matrix material can include a material, such as a wax, low melting point waxes such as carnauba wax, starch, starch derivatives, sugars, sugar alcohols, leucine, lipids, a polyol, a polyether, fructose, glucose, lactose, mannitol, trehalose, sucrose, raffinose, maltitol, lactitol, sorbitol, xylitol, erythritol, xylose, acorbose, melezitose, galactose, melibrose, isomaltose, a natural sugar extracts, malt beet sugar, corn sugar, high-fructose corn syrup, a sugar oligomers, polydextrose and dextrans with molecular weights less than 10,000 Daltons, a polyol, glycerol, sorbitol, ethylene glycol, propylene glycol, butanediol, polymeric derivatives of vitamin E, poly(propylene), and combinations.
- The DHM formulation can further include a plasticizer. The plasticizer can include a plasticizer, for example, triacetin, citrate ester, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and combinations. The plasticizer can also be low molecular weight polyols having aliphatic hydroxyls, poly(propylene glycol), low molecular weight poly(ethylene oxide) having an average molecular weight of less than about 500,000 Da, poly(ethylene glycol), D-alpha tocopheryl PEG 1000 succinate (TPGS), low molecular-weight polyethylene glycol, propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, triethylene glycol, tetraethylene glycol, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, allyl glycolate, vitamin E, and/or pressurized CO2.
- The DHM formulation can further include a permeabilizer. The permeabilizer can include caprylic acid, a caprylate salt, and/or sodium caprylate. The permeabilizer can also include a permeabilizer such as a fatty acid, a saturated fatty acid, and/or a fatty acid complexed with a cation, such as a metal cation, a metal divalent cation, a magnesium divalent cation, a calcium divalent cation, a zinc divalent cation, an iron divalent cation, a metal trivalent cation, an iron trivalent cation, a fatty acid salt, a fatty acid metallic soap, and combinations.
- The DHM formulation can further include an antioxidant. The DHM formulation can further include a coactive such as glutathione, L-cysteine, N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger toot, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, and combinations.
- The DHM formulation can further include a pH buffering agent. The pH buffering agent can be an acidic pH buffering agent, citric acid, a citrate salt, a sodium citrate, a potassium citrate, calcium citrate, and/or combinations.
- In an embodiment of the invention, in the DHM formulation, the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 3.5, and the DHM is solubilized or dissolved by an aqueous solution having a pH of at least 5.5. In an embodiment of the invention, the DHM comprises at least 20 wt % of the powder. In an embodiment of the invention, the crystallinity of the DHM is at most 10%. In an embodiment of the invention, the DHM formulation is homogeneous.
- In an embodiment of the invention, a dosage form includes the DHM formulation and an enteric coating that encapsulates the DHM formulation. The enteric coating can be a polymeric coating or a methacrylate copolymer coating.
- In an embodiment of the invention, a dosage form includes the DHM formulation of in a powder form and an aqueous liquid or a gel. The DHM formulation can be in a powder form which is mixed with or suspended in the aqueous liquid or the gel.
- In an embodiment of the invention, in the DHM formulation, the matrix material is poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA) and the DHM comprises at least 20 wt % of the DHM formulation.
- In an embodiment of the invention, a method for forming the dihydromyricetin (DHM) includes: mixing the dihydromyricetin (DHM) and the matrix material to form a compounding mixture; processing the compounding mixture in an extruder to form an extrudate; and collecting the extrudate as the dihydromyricetin (DHM) formulation. The operating temperature of the extruder can be less than the melting temperature of dihydromyricetin (DHM).
- In an embodiment of the invention, a method for reducing hangover symptoms includes: administering the dihydromyricetin (DHM) formulation to a patient suffering from hangover symptoms, so that the patient's hangover symptoms are reduced.
- In an embodiment of the invention, the dihydromyricetin (DHM) formulation can be used in preventing an alcohol use disorder, preventing alcoholism, treating an alcohol use disorder, treating alcoholism, or treating an alcohol overdose.
- In an embodiment of the invention, the dihydromyricetin (DHM) formulation can be used in increasing antioxidant capacity, neuroprotection, preventing Alzheimer's disease, treating Alzheimer's disease, inhibiting inflammation, protecting the kidney, protecting the liver, preventing or treating cancer, ameliorating a metabolic disorder, preventing diabetes, treating diabetes, or treating a bacterial infection.
- Embodiments of the invention are discussed in detail below. In describing embodiments, specific terminology is employed for the sake of clarity. However, the invention is not intended to be limited to the specific terminology so selected. A person skilled in the relevant art will recognize that other equivalent parts can be employed and other methods developed without parting from the spirit and scope of the invention. All references cited herein are hereby incorporated by reference in their entirety as if each had been individually incorporated.
- An embodiment of the present invention includes a method to improve the bioavailability of the molecule dihydromyricetin (DHM) through the process known as hot melt extrusion (HME) to form a hot melt extruded formulation. This method can include processing by HME of a combination of materials including DHM, additional beneficial molecules (e.g., co-actives), polymeric excipients, plasticizers, and permeability-enhancing compounds (permeabilizers). The final form of the product may comprise powders, granules, or tablets to be used in further formulations.
- The present invention can provide a hot-melt extrusion method and resultant formulation including a beneficial amount of DHM, additional beneficial molecules, polymeric excipients, plasticizers, and permeability-enhancing compounds. Improvements in bioavailability and pharmacokinetic parameters of DHM can be associated with this formulation method.
- In an embodiment, the formulation may be processed further in forms beyond powders, granules, and tablets for administration by various routes either by self-administration or administration by any number of routes known to a skilled artisan. In some embodiments, the formulation may be well suited to oral administration routes.
- Thomson, et al. (U.S. Pat. No. 3,239,370) discusses a method and process for coating substrates with films of molten random copolymer of ethylene and carboxylic acid. The polymer is hot melt extruded through a slit die to provide the film that is applied to a substrate in molten form before cooling into a solid state. [9] Schippers, et al. (U.S. Pat. No. 3,410,938) discusses processing thermoplastic polymers by conveying them down the barrel of a hot metal extruder by screw extrusion to remove trapped gases within the polymer and generate various morphologies of the polymer being processed.[10] McGinity, et al. (U.S. Pat. No. 6,488,963B1) discusses hot melt extrudable pharmaceutical formulations, which include therapeutic molecules dispersed within a high molecular weight poly(ethylene oxide) (PEO) matrix and may include plasticizers. [11] Miller, et al. (U.S. Pat. No. 9,504,658, U.S. Ser. No. 11/718,620) discusses dispersions of fine drug particles within polymeric and/or lipophilic polymeric matrices, e.g., of PEO, which can include other hydrophilic polymers, e.g., hydroxypropyl methylcellulose (HPMC) and polyvinyl acetate (PVA), that are processed by HME. [12] Alderman, et al. (U.S. Pat. No. 4,678,516) discusses a method for prolonging the release of therapeutically active molecules by dispersing them within a thermoplastic polymeric matrix consisting of hydroxypropyl methylcellulose (HPMC) and plasticizers. [13] Brough, et al. (U.S. Pat. No. 8,486,423, U.S. Ser. No. 12/196,154) discusses a method of dispersing pharmaceutically relevant active ingredients (APIs) into homogeneous composites, including thermoplastic polymers that can molecularly dissolve the API or provide a matrix for dispersion of fine particles of the API, that can be further processed by hot melt extrusion. [14] Fischer, et al. (U.S. Pat. No. 8,298,581, U.S. Ser. No. 10/550,685) discusses a matrix composition for the delivery of APIs as oral formulations and a double-coating process including a polymer from the PEO group and a polymer from a copolymer of ethylene oxide and propylene oxide.[15] Yang, et al. (U.S. Pat. No. 8,603,514, U.S. Ser. No. 11/775,484) and Fuisz, et al. (US Pat. Applic. Pub. 2007-0281003 A1, U.S. Ser. No. 11/674,223) discuss pharmaceutically relevant compositions for the formation of films containing one or more entrapped APIs and other excipients or plasticizers in a polymeric matrix by HME.[16, 17] Bernstein, et al. (U.S. Pat. No. 6,730,322B1) discusses the integration of hydrophobic components into a microsphere polymeric matrix to alter the release characteristics of entrapped drugs. McAllister, et al. (US Pat. Applic. Pub. 2003-0049311 A1, 10/060,603) and McAllister, et al. (U.S. Pat. No. 7,842,308, Ser. No. 10/470,439) discuss pharmaceutical formulations for injection molding and polymeric matrices for film formation.[18-20]
- Dihydromyricetin (DHM), a flavonoid compound isolated from the Hovenia plant can “sober-up” rats inebriated with alcohol[2], prevent predisposed rats from becoming alcoholics[2], return alcoholic rats to baseline levels of alcohol consumption[2], reduce hangover symptoms[2], and prevent fetal alcohol spectrum disorders in the offspring of rats exposed to significant amounts alcohol during pregnancy.[2] DHM can be dissolved in a solvent, such as dimethylsulfoxide (DMSO). DHM can be complexed with a metal, such as a divalent alkali earth metal, divalent magnesium (Mg(II), Mg+2), a divalent transition metal, divalent iron (Fe(II), Fe+2), divalent copper (Cu(II), Cu+2), a trivalent transition metal, or trivalent iron (Fe(III), Fe′).
- DHM has unique physicochemical properties including low solubility, high hydroxyl functional group content, and unknown thermal stability, rendering the processing of DHM and other flavonoids under hot melt extrusion (HME) conditions difficult.
- DHM demonstrates pharmacological properties for successful medical treatment of alcohol use disorders (AUDs)[21-23]. Given limited available pharmacotherapies for AUDs and these being limited by low patient compliance, because of the adverse effects they may cause, therapies for the treatment of AUDs should be advanced, e.g., through DHM therapeutic strategies. [24]
- In addition to DHMs potential for the treatment of AUDs, which, without being bound by theory, may be achieved through DHM's inhibiting the effect of alcohol on GABAA receptors (GABAARs) in the brain, DHM and the Hovenia plant it is isolated from have shown efficacy in mitigating liver injuries[25-27], decreasing alcohol and acetaldehyde concentrations in the blood via enhancing ADH and ALDH activity[28, 29], and eliminating alcohol-induced excessive free radicals.[30] DHM has been observed to have oxidative stress-mediating activity, i.e., increase antioxidant capacity for scavenging reactive oxygen species, which may result in neuroprotective, nephroprotective (kidney protecting), and hepatoprotective (liver protecting) effects, which may ameliorate, for example, the effects of hypobaric hypoxia, side effects of the chemotherapeutic agent cisplatin, and detrimental effects of ethanol. DHM may have a neuroprotective role in Alzheimer's and Parkinson's diseases. DHM can also inhibit inflammation. DHM can also have anticancer activity and regulate cell proliferation and apoptosis. DHM can mediate metabolism, and may be useful in ameliorating certain metabolic disorders, such as diabetes, weight gain, hyperlipidemia, and atherosclerosis. DHM exhibits antibacterial activity (Li, H. et al., “The Versatile Effects of Dihydromyricetin in Health”, Evidence Based Complementary & Alternative Medicine 2017, Art. ID 1 053617).
- A DHM formulation designed to reduce alcohol's negative effects when taken after alcohol consumption is covered under U.S. Pat. No. 9,603,830 B2 (granted on Mar. 28, 2017) and is sold in the US under the brand name Thrive+®.
- Despite promising results in rats, one challenge in translating DHM's efficacy to humans in a commercially viable way is DHM's oral bioavailability of less than 5% [31]. DHM can have poor stability. DHM is a BCS class IV drug limited by having the properties of low solubility and low permeability. In the context of successfully commercialized drugs, DHM requires large doses for efficacy. Because DHM is a naturally occurring organic compound isolated from an herb, a DHM formulation can be classified as a food (or dietary supplement) under the Dietary Products designation.
- This invention addresses the problem of poor bioavailability and stability of DHM through the use of hot melt extrusion (HME). By dispersing DHM within a set of excipients using HME, e.g., excipients which are preferably chiefly polymeric, DHM can have higher supersaturation, and may exhibit increased bioavailability, be released more slowly upon ingestion, and exhibit enhanced dissolution and release kinetics, longer sustained release, higher concentrations, and improved stability with respect to low pH gastric juices and enzymes, which can cause degradation and quenching of DHM activity, than when administered in a pure form. Furthermore, the DHM HME formulation may possess improved ability to penetrate intestinal barriers, to allow DHM to reach the bloodstream more effectively and efficiently.
- Hot melt extrusion (‘HME’) is an industrial process that can be used to create uniform polymer products such as tubes, sheets, and foams.[3-7] HME can be employed to disperse active pharmaceutical ingredients (APIs) within solid polymer matrices. [3, 5, 6] In this process, an API and polymer excipient(s) are fed into an extruder. These are then conveyed by single or double-screws down the barrel of the device while undergoing melting, mixing, dispersing, and finally cooling processes.
- HME can be used to confer improved bioavailability and API dissolution in a final application. A limitation of HME is that the active compound and excipient(s) are subjected to elevated temperatures which may prompt or accelerate degradation of an API.
- The term “hot-melt extrudable” refers to a compound or formulation that may be hot-melt extruded. A hot-melt extrudable polymer is one that is sufficiently rigid for an intended use at standard ambient temperature and pressure, but is capable of deformation or forming a liquid or semi-liquid state under elevated heat or pressure.
- In an embodiment of the invention, a composition for hot-melt extrusion does not include a plasticizer. In another embodiment of the invention, a composition for hot-melt extrusion includes one or more plasticizers. Although the process according to the invention has been called a hot-melt extrusion, other equivalent and similar processes such as injection molding, hot dipping, melt casting, and compression molding may be used. By using any of these methods, the formulation may be shaped as needed according to the desired mode of administration, e.g. powders, tablets, pills, lozenges, suppositories, capsules and the like. The hot-melt extrusion process employed in some embodiments of the invention is conducted at an elevated temperature, i.e., the heating zone(s) of the extruder is above room temperature (about 20° C.). An operating temperature range should be selected that minimizes the degradation or decomposition of the therapeutic compound (e.g., DHM) during processing. For example, the operating temperature range can be in the range of from about 60° C. to about 160° C. and can be set for one or more extruder heating zone(s).
- In a hot-melt extrusion (HME) process according to the invention an effective amount of therapeutic compound(s) is mixed with matrix polymer(s), a plasticizer, such as polyethylene glycol (PEG), permeability-enhancers, and/or other excipients. Other components may be added for various embodiments of the invention. The mixture is then placed in the extruder hopper and passed through the heated area of the extruder at a temperature which melts or softens the matrix polymer, excipient(s), and/or plasticizer, if present, to form a matrix throughout which the therapeutic compound is dispersed. The molten or softened mixture then exits via a die, or other such element, at which time the mixture (now called the extrudate) begins to harden. Since the extrudate is still warm or hot upon exiting the die, it may be easily shaped, molded, chopped, ground, shaped into beads, cut into strands, tableted, or otherwise processed to the desired physical form. The extruder used to practice the invention may be any commercially available or custom-built model equipped to handle dry feed and having a solid conveying zone, one or multiple heating zones, and an extrusion die. A two-stage Single Screw extruder, such as that manufactured by C. W. Brabender Instruments Incorporated (NJ), is one such apparatus. It can be advantageous for the extruder to possess multiple separate temperature controllable heating zones.
- Several conditions may be varied during the extrusion process to arrive at a particularly advantageous formulation. Such conditions include, by way of example, formulation composition, feed rate, operating temperature, extruder screw RPM, residence time, die configuration, heating zone length, and/or extruder torque and/or pressure.
- For example, the extrusion conditions may be selected to produce a formulation that is a homogeneous, e.g., DHM is homogeneously dispersed in a matrix material or in a combination of matrix material(s), plasticizer(s), and/or permeabilizer(s).
- HME can produce various forms of solid dispersions. These may include, but are not limited to, pharmaceutically-relevant dosage forms, such as powders, pellets, cylinders, tubes, granules, and flakes. These can be processed further into a desired morphology with desired surface characteristics.
- In an embodiment of the present invention, the use of hot melt extrusion in the preparation of pharmaceutical dosage forms to effectively deliver DHM has several advantages. HME is scalable, e.g., it can be used at the lab scale, the pilot plant scale, and to mass produce large quantities of product. It allows for DHM to be formulated with a wide variety of excipient(s) and plasticizer(s) to allow for maximum effectiveness as needed for various administration routes. Furthermore, HME can be solvent free, thus reducing the need for a subsequent solvent removal step and reducing the potential for solvent-induced toxicity.[7]
- The invention includes, but is not limited to, a combination of materials including the active ingredient DHM and/or other flavonoids, additional active molecules and co-actives, permeability enhancers, excipients (including matrix materials), plasticizers, and an enteric coating. In an embodiment, the HME dosage form includes dihydromyricetin (DHM) and a coactive, such as L-cysteine, N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger root, vitamin B, vitamin C, vitamin E, an electrolyte, a sugar, an antioxidant, and/or glutathione.
- A permeability-enhancer or permeabilizer is an agent that enhances the permeation of a drug compound through the epithelial cell layer in the gastrointestinal (GI) tract and, hence, enhances the amount of drug entering the bloodstream. Permeability-enhancers have been reviewed by Aungst and Whitehead[32-35]. The list of agents presented by Aungst in Table I and Whitehead in Table I are incorporated into this patent in their entirety.
- Examples of permeability-enhancers are fatty acids, a saturated fatty acid, caprylic acid, a caprylate salt, sodium caprylate, a fatty acid complexed with a cation, such as a metal cation, a metal divalent cation, a magnesium (Mg(II), Mg+2), calcium (Ca(II), Ca+2), or zinc divalent cation (Zn(II), Zn+2), iron divalent cation (Fe(II), Fe+2), a metal trivalent cation, iron trivalent cation (Fe(III), Fe+3), a fatty acid salt, a fatty acid metallic soap, and combinations of these. For example, capric acid and its salts are permeabilizers that are currently clinically approved for use in an ampicillin suppository. The caprates and other long-chain saturated fatty acids and their salts can be incorporated into the hot melt extrusion (HME) process. Their hydrophobicity can be enhanced by complexing them, for example, with divalent cations such as those of magnesium (Mg(II), Mg+2), calcium (Ca(II), Ca+2), or zinc, divalent iron, or trivalent iron. Permeabilizers are optional additions to the formulation. When they are used, the mass ratios of permeabilizer to DHM in the hot melt extruded formulation (extrudate) produced can range from 1:100 to 100:1.
- Excipients and matrix materials are defined as materials that aid in the formulation, stability, and/or release characteristics of the active molecule DHM. For example, homopolymers, copolymers, and amphiphilic copolymers can be used as excipients and matrix materials. The matrix material can constitute from 0.1 wt % to 99 wt % of the combined mass of the active agent(s) and excipients by weight of the final solid form. When it is desirable for the matrix material to prevent aggregation of the active domains into larger aggregates, the matrix material can constitute more than 20% or more than 40% of the combined mass of the active agent(s) and matrix material.
- Exemplary excipients and matrix materials include low melting point waxes such as carnauba wax, cellulose, methyl cellulose, ethyl cellulose, polyvinylpyrrolidone (PVP) and its copolymers such as polyvinylpyrrolidone-vinyl acetate (PVP-VA), poly(ethylene-co-vinyl acetate), various grades of polyethylene glycol (PEG), polyethylene oxide (PEO), cellulose esters, cellulose acrylates, cellulose derivatives, polymethacrylate, polymethacrylate derivatives, polyoxyethylene-polyoxypropylene block copolymers (also referred to as poloxamers), hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose (HPMC), HPMC derivatives, polylactic acid (PLA), poly(glycolide) (PGA), and poly(lactide-co-glycolide) (PLGA), poly(caprolactone) (PCL), starch, starch derivatives, sugars, sugar alcohols, waxes, leucine, lipids, carboxymethylcellulose, sodium carboxymethylcellulose, carboxymethylcellulose salts, hydroxyethylcellulose, methacrylic acid copolymers, poly(methyl methacrylate) (PMMA), and ethylene glycol-vinyl glycol copolymer.
- Examples of excipients and matrix materials include polyoxyethylene alkyl ethers, polyoxyethylene castor oils, polycaprolactam, hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose (HPMC), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate (HPMCAT), hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate (CAS), methyl cellulose acetate succinate (MCAS), poly(methacrylic acid-co-methyl methacrylate) 1:1 (e.g., Eudragit® L100, Evonik Industries AG), poly(methacrylic acid-co-methyl methacrylate) 1:2 (e.g., Eudragit® S100), poly(methacrylic acid-co-ethyl acrylate) 1:1 (e.g., Eudragit® L100-55), a polyol, a polyether, a cellulosic polymer, sugars and sugar alcohols, for example, fructose, glucose, lactose, mannitol, trehalose, sucrose, raffinose, maltitol, lactitol, sorbitol, xylitol, erythritol, xylose, acorbose, melezitose, galactose, melibrose, and isomaltose, natural sugar extracts, for example, malt beet sugar, corn sugar, high-fructose corn syrup, sugar oligomers, such as polydextrose and dextrans with molecular weights less than 10,000 Daltons, polyols such as glycerol, sorbitol, ethylene glycol, propylene glycol, butanediol, and other oligomers, low molecular-weight oligomers, such as low molecular weight polyethylene glycol and low molecular weight poly(methyl methacrylate), ethoxylated castor oil, polyoxyl hydrogenated castor oil, polyoxyl 40 hydrogenated castor oil, polymeric derivatives of vitamin E, polyethoxylated sorbitan, and polyoxyethylene sorbitan monooleate.
- The excipients and matrix materials can include amphiphilic block copolymers, for example, polystyrene-block-polyethylene glycol (PS-b-PEG), polylactic acid-block-polyethylene glycol (PLA-b-PEG), and poly(lactic-co-glycolic acid)-block-polyethylene glycol (PLGA-b-PEG).
- Examples of excipients and matrix materials include derivatives of the above, copolymers of the above, and combinations of the above.
- In an embodiment, the matrix material includes components with a molecular weight of less than 1,000,000 Daltons (Da), less than 100,000 Daltons, less than 10,000 Daltons, less than 5000 Daltons, or less than 2000 Daltons.
- The matrix material can include a polymer. A polymer is formed of several monomer units bound to each other. For example, a polymer can be a linear polymer, a branched polymer, or a cyclic polymer. In a cyclic polymer, a set of monomers can be bound to each other to form a ring. In a noncyclic polymer, there is no set of monomers that are bound to each other to form a ring (although atoms within a given monomer unit of the polymer still may be in a ring structure, e.g., a cyclopentyl, furan, furanose, cyclohexyl, pyran, pyranose, benzene, or saccharide structure). For example, cyclodextrin is a cyclic polysaccharide. By contrast, cellulose is a linear polysaccharide formed of several hundred to many thousands of D-glucose monomers. Gum arabic includes arabinogalactan, formed of arabinose and galactose monomers.
- Certain polymeric excipients and matrix materials marketed under trade names by manufacturers may include the following:
- BASF: Povidones, copovidones, methacrylic acid copolymers, ethylene glycol-vinyl glycol copolymers, Poloxamer 407, Poloxamer 188, poly ethylene glycols, polyoxyl 40 hydrogenated castor oils, and polymeric derivatives of vitamin E marketed by BASF under trade names SOLUPLUS, KOLLIDON VA 64, KOLLIDON 12 PF, KOLLIDON 17 PF, KOLLIDON 30, KOLLIDON 90 F, KOLLIDON SR, KOLLICOAT MAE 100P, KOLLICOAT IR, KOLLICOAT PROTECT, KOLLIPHOR P 407, KOLLIPHOR P407 MICRO, KOLLIPHOR P188, KOLLIPHOR P188 MICRO, KOLLISOLV PEG, KOLLIPHOR RH 40, KOLLIPHOR TPGS.
The Dow Chemical Company: Polymers with trade names METHOCEL, ETHOCEL, POLYOX, and AFFINISOL marketed by the Dow Chemical Company.
Evonik Corporation: Polymers with trade names EUDRAGIT® (methacrylates) and RESOMER, marketed by Evonik Corporation.
Ashland: Polymers with trade names AquaSolve hypromellose acetate succinate, Aqualon ethylcellulose, Aqualon sodium carboxymethylcellulose, Aquarius control film coating systems, Aquarius prime film coating systems, Aquarius protect film coating systems, Aquarius film coating systems, Aquarius preferred film coating systems, Benecel methylcellulose and hypromellose, Blanose sodium carboxymethylcellulose, CAVAMAX native cyclodextrins, Cavitron cyclodextrin, CAVASOL cyclodextrin, Klucel hydroxypropylcellulose, Natrosol hydroxyethylcellulose, Pharmasolve N-methyl-2-pyrrolidone, Plasdone S-630 copovidone, Plasdone povidone, and Polyplasdone crospovidone (cross linked polyvinyl N-pyrrolidone) marketed by Ashland Global Holdings Inc. - The foregoing lists of materials are not intended to indicate that all of these materials are equivalent and/or equally suitable.
- The polymer matrix material can have a glass transition temperature (Tg) of at least 50° C., 60° C., 70° C., 80° C., 90° C., 100° C., 110° C., 115° C., 120° C., 125° C., 130° C., 150° C., 175° C., 200° C., or 250° C. For example, hydroxypropyl methyl cellulose acetate succinate (HPMCAS) has a glass transition temperature (Tg) of about 120° C.
- The polymer matrix material may be selected to adjust the formulation's release profile, e.g., to adjust the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM.
- In an embodiment, polymers, such as one or more of those listed above, may also be incorporated as enteric coatings which coat a final tablet form of a DHM hot-melt extruded (HME) formulation and provide additional stability or sustained release benefits. For example, including an enteric coating in the formulation may alter the formulation's release profile, e.g., may alter the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM. For example, the enteric coating may be a methacrylate copolymer coating.
- The term “plasticizer” includes compounds capable of plasticizing the polymeric excipients, including the polymer matrix material, used. The plasticizer may lower the glass transition temperature or softening point of the excipient(s) in order to allow for lower processing temperature, extruder torque, and pressure during the hot-melt extrusion (HME) process. Plasticizers, such as PEG and low molecular weight PEO, can broaden the average molecular weight of the polymeric excipients used, thereby lowering the glass transition temperature or softening point of the composition being extruded. Plasticizers can reduce the viscosity of a polymer melt, thereby allowing for lower processing temperature and extruder torque during hot-melt extrusion. A plasticizer may impart advantageous physical properties to the extruded formulation. As used herein, the term “low molecular weight PEO” means poly(ethylene oxide) homopolymer having an average molecular weight less than about 500,000.
- In an embodiment according to the invention, the composition that undergoes hot melt extrusion (HME) and the extruded formulation do not include a plasticizer. In an embodiment according to the invention, the composition that undergoes hot melt extrusion (HME) and the extruded formulation include a plasticizer.
- Including a plasticizer in the formulation may alter the formulation's release profile, e.g., may alter the rate at and duration of time over which the formulation releases an active pharmaceutical ingredient (API), such as DHM. Increasing the amount of plasticizer in the formulation may increase the release rate of the therapeutic compound (API, e.g., DHM). A combination of plasticizers may be used in the composition to be extruded and the extruded formulation.
- Plasticizers that may be used in an embodiment of the invention include, by way of example and without limitation, low molecular weight polymers, oligomers, copolymers, oils, small organic molecules, low molecular weight polyols having aliphatic hydroxyls, ester-type plasticizers, glycol ethers, poly(propylene glycol), multi-block polymers, single block polymers, low molecular weight poly(ethylene oxide) (e.g., having an average molecular weight of less than about 500,000 Da), and poly(ethylene glycol).
- Plasticizers that may be used in an embodiment of the invention include, but are not limited to triacetin, citrate ester, vitamin E, D-alpha tocopheryl PEG 1000 succinate (TPGS), molecular surfactants, low molecular-weight polyethylene glycol, pressurized CO2, propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, styrene, a glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and allyl glycolate.
- Examples of plasticizers include derivatives of the above, copolymers of the above, and combinations of the above.
- The foregoing lists of materials are not intended to indicate that all of these materials are equivalent and/or equally suitable.
- The amount of plasticizer used in the formulation may affect the formulation's properties. The amount of plasticizer selected for use in the composition for HME and the formulation produced can will depend upon the plasticizers composition, physical properties, effect upon the excipient(s), interaction with other components of the formulation, ability to solubilize the therapeutic compound, and/or other factors.
- In some embodiments, DHM constitutes at least 0.1 wt %, 1 wt %, 2 wt %, 3 wt %, 5 wt %, 7 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, 35 wt %, 40 wt %, 50 wt %, 55 wt %, 60 wt %, 70 wt %, 80 wt %, 90 wt %, 95 wt %, 98 wt %, or 99 wt % of the HME formulation, relative to the total mass of the formulation, including all other excipients and matrix materials.
- In some embodiments, the concentration of all other components, and particularly excipients and matrix materials, in the formulation may range from 0.001 wt % to 0.01 wt %, or from 0.01 wt % to 0.1 wt %, or from 0.1 wt % to 1 wt %, or from 1 wt % to 10 wt %, or from 10 wt % to 99.9 wt %, depending on the desired release profile, the pharmacological activity and toxicity of the therapeutic compound, such as DHM and any coactive, and other such considerations.
- The resulting formulations of embodiments of the present invention are useful and suitable for delivery in animals and humans and may be administered by a variety of methods. Such methods include, by way of example and without limitation: oral, nasal, buccal, rectal, ophthalmic, otic, urethral, vaginal, or sublingual dosage administration. Such methods of administration and others contemplated within the scope of the present invention are known to the skilled artisan. In vivo stability of the present formulation may vary according to the physiological environment to which it is exposed and the matrix material, excipients, and plasticizer used. Therefore, the necessity for or frequency of readministration may be different for various formulations.
- The formulation of the present invention may be provided in a variety of ways, for example, powder, tablet, and capsule dosage forms. Additional components that would not significantly prohibit the hot-melt extrusion (HME) process may be added to the formulation prior to hot-melt extrusion. That is, such additional components should still allow for formulation using the hot-melt extrusion process.
- For oral, buccal, and sublingual administration, the formulation may be in the form of a gel cap, caplet, tablet, capsule, suspension, or powder. Alternatively, the formulation may be in the form of a mixture with or suspension in, e.g., a DHM-containing powder according to an embodiment of the invention mixed with or suspended in, a consumable (edible) liquid (e.g., an aqueous liquid, such as water), such as a drink or liquid concentrate. Alternatively, the formulation may be in the form of a mixture with or suspension in, e.g., a DHM-containing powder according to an embodiment of the invention mixed with or suspended in, an edible gel. For rectal administration, the formulation may be in the form of a suppository, ointment, enema, tablet, or cream for release of compound into the intestines, sigmoid flexure, and/or rectum.
- In solid dosage forms, the compounds can be combined with conventional carriers, for example, one or more of the following: binders, such as acacia, corn starch, or gelatin; disintegrating agents, such as corn starch, guar gum, potato starch, or alginic acid; lubricants, such as stearic acid or magnesium stearate; and inert fillers, such as lactose, sucrose, or corn starch.
- It is contemplated that either one or a combination of long-acting, sustained-release, controlled-release, and/or or slow-release dosage forms may be used in the present invention. This may be desirable, if continuous exposure of an animal or a human to the active ingredient(s) (e.g., DHM) is the desired outcome. The polymers and formulations useful in this case can include derivatized cellulosic polymers of the type described in the Dow Chemical Company Technical Bulletin “Using Dow Excipients for Controlled Release of Drugs in Hydrophilic Matrix Systems”, 2006 and marketed under the trade name METHOCEL (methylcellulose and hydroxypropyl methylcellulose (HPMC) polymers). The course and duration of administration of and the dosage requirements for the formulation of the present invention will vary according to the animal or human being treated, the formulation used, the method of administration used, the severity of the condition being treated, the co-administration of other drugs, and other factors.
- Increased bioavailability can be achieved using HME processing by tuning the interactions between the drug (e.g., DHM) and the HME polymer. For example, the drug (e.g., DHM) can be substantially soluble in the molten polymer phase, which can include one or more excipient(s) and/or plasticizers, such that upon cooling and solidification, that drug is prevented from substantially crystallizing. Capturing the drug (e.g., DHM) in an amorphous, or non-crystalline-associated state (which can be a high-energy state), can result in a higher dissolution level or a supersaturation level, when dissolved in vitro or in vivo. Thermodynamic reasons for this increase in solubility have been discussed by Hu, Johnson & Williams.[36]
- Commercially supplied pure DHM can be entirely (100%) or nearly entirely crystalline.
- The crystallinity of the DHM in the hot-melt extruded (HME) formulation can be qualitatively assessed or quantitatively measured by techniques, such as polarized light microscopy (PLM), differential scanning calorimetry (DCS), and powder X-ray diffraction (P-XRD). The DHM in the hot-melt extruded (HME) formulation can have a crystallinity of less than or equal to 90%, 80%, 60%, 50%, 40%, 30%, 20%, 25%, 20%, 15%, 10%, 7%, 5%, 3%, 2%, or 1%. The DHM in the hot melt extruded formulation (extrudate) can be amorphous.
- In an embodiment, the DHM in the hot melt extrusion formulation (extrudate) does not dissolve in and/or is not solubilized by an aqueous solution having a pH of at most (i.e., less than or equal to) 4.8, 4.5, 4, 3.5, 3.2, 3, 2.7, 2.5, 2.3, 2, 1.8, 1.5, or 1. The chyme that is expelled by the stomach, through the pyloric valve, has a pH of approximately 2. Gastric juices lead to material in the stomach having a pH in the range of from 1.5 to 3.5, and this low pH in the stomach and the enzymes active in the stomach at this low pH may result in degradation of DHM and quenching of DHM activity.
- In an embodiment, the DHM in the hot-melt extruded (HME) formulation dissolves in and/or is solubilized by water (pH of 7) and/or an aqueous solution having a pH of at least (i.e., greater than or equal to) 5, 5.3, 5.5, 5.8, 6, 6.2, 6.5, 6.7, 7, 7.2, or 7.5. Bile released into the duodenum and/or pancreatic secretions of sodium bicarbonate increase the pH of the chyme. For example, the pH of chyme and material in the intestine (bowel) can range from 5.5 to 7, for example, can be 7. The dissolution and/or solubilization of the DHM in the hot melt extruded formulation in the intestine, for example, the small intestine, can result in the DHM being absorbed by the wall of the intestine, for example, the wall of the small intestine, and into the blood.
- For example, hydroxypropyl methyl cellulose acetate succinate (HPMCAS) is insoluble in an aqueous solution of acidic (low) pH, but is soluble in an aqueous solution of neutral or alkaline (high) pH. Therefore, a hot-melt extruded (HME) formulation including HPMCAS and DHM can retain the DHM at an acidic (low) pH, e.g., a pH of 3.5 or less, but release the DHM at a neutral or alkaline (high) pH, e.g., a pH of 7 or greater.
- A pH buffering agent can be included in such a hot-melt extruded (HME) formulation.
- Inclusion of an acidic component in such a hot-melt extruded (HME) formulation, such as an acidic pH buffering agent (i.e., a buffering agent that maintains an acidic pH, a pH of less than 7), e.g., citric acid or a citrate salt (e.g., a sodium citrate, a potassium citrate, calcium citrate, and/or combinations), can stabilize an aqueous solution formed with the hot-melt extruded (HME) formulation, so that the DHM is not released into the aqueous solution or so that the release of the DHM into the aqueous solution is delayed.
- The polymer matrix material can be selected, so that it is moderately soluble (e.g., from 0.01 g/100 mL to 3 g/100 mL, or from 0.1 g/100 mL to 1 g/100 mL) in water. Moderate solubility in water allows the polymer matrix material to dissolve in the body of an organism and release the DHM.
- The dissolution and release kinetics of DHM are studied under different conditions; three protocols are described as follows. [37]
- Release Kinetics in Vitro: Simulated gastric fluid (FaSSGF) and intestinal fluids (FaSSIF and FeSSIF) are prepared according to the manufacturer's instructions. Dissolution tests are performed with hot-melt extruded (HME) DHM-containing powders or tablets with the appropriate controls.
- Release under Gastric Conditions: DHM-containing hot melt extruded (HME) powder samples are suspended in prewarmed FaSSGF (37° C.) to achieve a drug (DHM) concentration of roughly 10-100× the previously determined equilibrium solubility in the FaSSGF fluid (e.g., 75 μg/mL) by pipetting up and down vigorously multiple times. The samples are incubated for the duration of the study (e.g., 30 min) at 37° C. (NesLab RTE-111 bath circulator, Thermo Fisher Scientific, Waltham, Mass.) without agitation to mimic physiological gastric conditions and transition time in the stomach. Aliquots can be taken, for example, at 1, 5, 10, 15, 30, 60, 120, and 360 min. To analyze the free DHM concentration, each aliquot can be centrifuged at 28000 g for 5 min to pellet suspended particles. The supernatant is frozen and lyophilized; the remaining solids are reconstituted in, for example, 2:8 THF (tetrahydrofuran):acetonitrile to dissolve DHM and precipitate out lipids and salts from the release media. The samples are then diluted as appropriate to fall within the detection range and analyzed by high-performance liquid chromatography (HPLC), with the mobile phase as 80:20 H2O:acetonitrile (each with 0.05% trifluoroacetic acid), and with detection with UV-Vis at 290 nm. The concentration of DHM is then calculated based on a calibration curve.
- Release under Intestinal Conditions: DHM-containing hot melt extruded (HME) powder samples are suspended in prewarmed (37° C.) Fed State Simulated Intestinal Fluid (FeSSIF) or Fasted State Simulated Intestinal Fluid (FaSSIF) to achieve a drug (DHM) concentration of roughly 10-100× the previously determined equilibrium solubility in the FeSSIF or FaSSIF fluid by pipetting up and down vigorously multiple times. The equilibrium solubility of crystalline DHM in FeSSIF was measured to be about 140 μg/mL, and the equilibrium solubility of crystalline DHM in FaSSIF is about 50 μg/mL. Aliquots are taken at, for example, 1, 5, 10, 15, 30, 60, 120, and 360 min and centrifuged at, for example, 28000 g for 10 min. The supernatant is frozen and lyophilized; the remaining solids are reconstituted in, for example, 2:8 THF (tetrahydrofuran):acetonitrile to dissolve DHM and precipitate out lipids and salts from the release media. The samples are then diluted as appropriate to fall within the detection range and analyzed by HPLC, with the mobile phase as 80:20 H2O:acetonitrile (each with 0.05% trifluoroacetic acid), and with detection with UV-Vis at 290 nm. The concentration of DHM is then calculated based on a calibration curve.
- FaSSIF is a biorelevant intestinal media representing the fasted state intestinal fluid, and FeSSIF is another biorelevant intestinal media representing the fed state intestine fluid. FaSSIF and FeSSIF have different compositions. For example, components of FaSSIF include 3 mM taurocholate, 0.75 mM phospholipids, 148 mM sodium, 106 mM chloride, and 29 mM phosphate, while components of FeSSIF include 15 mM taurocholate, 3.75 mM phospholipids, 319 mM sodium, 203 mM chloride, and 144 mM acetic acid. In in vivo tests, the presence of food changes the pH and composition of fats and surfactants in the intestinal fluid. FaSSIF has a higher pH (6.5) than FeSSIF (5.0) and has lower levels of fat.
- The intestine can be the site of absorption for oral dosage forms, thus understanding the solubility of a drug or active ingredient in the intestinal fluid can be important.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 15 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 15 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 30 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 30 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 60 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 60 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 120 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 120 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fasted state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 360 minutes over that of pure DHM.
- For example, the dissolution kinetics of DHM in a hot-melt extruded (HME) formulation in an embodiment of the present invention in in vitro dissolution tests in simulated fed state fluid can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, or 250% after 360 minutes over that of pure DHM.
- DHM-containing samples (e.g., hot-melt extruded (HME) formulations in an embodiment of the present invention) can be administered (e.g., through oral gavage) to an animal (e.g., a rat or a mouse) at 10 mg DHM/kg body weight, 75 mg DHM/kg body weight, or another dosage in an in vivo study, and a pharmacokinetic study can be carried out to evaluate animal pharmacokinetics. The plasma concentration of DHM can be determined, for example, using a Waters Acquity ultra performance liquid chromatography system equipped with an electrospray ionization mass spectrometry system (Waters, Milford, Mass.), in accordance with a previous report [38], or an equivalent analytical analysis system.
- An animal dosed with a hot melt extrusion formulation containing DHM according to the present invention can show increased blood maximum concentrations, relative to dosing with pure DHM powder, of 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, 250%. The area under the curve (AUC) for 24 hours can be increased by 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 100%, 250% over the value associated with dosing with pure DHM powder.
- Several nonlimiting Aspects of the invention are set forth below.
- Aspect 1. A dihydromyricetin (DHM) formulation, comprising:
- dihydromyricetin (DHM) and
- a matrix material,
- wherein the DHM is dispersed within the matrix material and
- wherein the matrix material is a solid.
- Aspect 2. The DHM formulation of Aspect 1, wherein the matrix material comprises a polymeric matrix material.
Aspect 3. The DHM formulation of any one of Aspects 1 through 2, wherein the matrix material comprises cellulose and/or a cellulose derivative.
Aspect 4. The DHM formulation of any one of Aspects 1 through 3, wherein the matrix material comprises hydroxypropyl methyl cellulose (HPMC).
Aspect 5. The DHM formulation of any one of Aspects 1 through 4, wherein the matrix material comprises a material selected from the group consisting of cellulose ester, cellulose acrylate, methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose (HPC), hydroxypropyl methylcellulose propionate succinate, hydroxypropyl methyl cellulose phthalate (HPMCP), hydroxypropyl methyl cellulose acetate succinate (HPMCAS), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, carboxymethyl ethylcellulose (CMEC), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), hydroxypropyl methylcellulose propionate phthalate, hydroxypropyl methylcellulose acetate trimellitate (HPMCAT), hydroxypropyl methylcellulose propionate trimellitate, cellulose acetate succinate (CAS), methyl cellulose acetate succinate (MCAS), carboxymethylcellulose, carboxymethylcellulose salt, sodium carboxymethylcellulose, a cellulose polymer, and combinations.
Aspect 6. The DHM formulation of any one of Aspects 1 through 5, wherein the matrix material comprises polyethylene oxide (PEO).
Aspect 7. The DHM formulation of any one of Aspects 1 through 6, wherein the matrix material comprises a material selected from the group consisting of polyoxyethylene-polyoxypropylene block copolymers (also referred to as poloxamers), polyoxyethylene alkyl ethers, polyoxyethylene castor oils, a low molecular-weight oligomer of polyethylene glycol, an ethylene glycol-vinyl glycol copolymer, polyoxyethylene castor oils, ethoxylated castor oil, polyoxyl hydrogenated castor oil,polyoxyl 40 hydrogenated castor oil, polyethoxylated sorbitan, polyoxyethylene sorbitan monooleate, and combinations.
Aspect 8. The DHM formulation of any one of Aspects 1 through 7, wherein the matrix material comprises a material selected from the group consisting of polyvinyl pyrrolidone (PVP) and poly(vinyl pyrrolidone-co-vinyl acetate) (PVP-VA).
Aspect 9. The DHM formulation of any one of Aspects 1 through 8, wherein the matrix material comprises a material selected from the group consisting of poly(methyl methacrylate) (PMMA), low molecular weight poly(methyl methacrylate), polymethacrylate, methacrylic acid copolymers, polymethacrylate derivatives, poly(methacrylic acid-co-methyl methacrylate) 1:1, poly(methacrylic acid-co-methyl methacrylate) 1:2, poly(methacrylic acid-co-ethyl acrylate) 1:1, and combinations.
Aspect 10. The DHM formulation of any one of Aspects 1 through 9, wherein the matrix material comprises a material selected from the group consisting of polycaprolactam, polycaprolactone (PCL), polylactic acid (PLA), polyglycolic acid (PGA), poly(lactic-glycolic acid) (PLGA), and combinations.
Aspect 11. The DHM formulation of any one of Aspects 1 through 10, wherein the matrix material comprises a material selected from the group consisting of a wax, low melting point waxes such as carnauba wax, starch, starch derivatives, sugars, sugar alcohols, leucine, lipids, a polyol, a polyether, fructose, glucose, lactose, mannitol, trehalose, sucrose, raffinose, maltitol, lactitol, sorbitol, xylitol, erythritol, xylose, acorbose, melezitose, galactose, melibrose, isomaltose, a natural sugar extracts, malt beet sugar, corn sugar, high-fructose corn syrup, a sugar oligomers, polydextrose and dextrans with molecular weights less than 10,000 Daltons, a polyol, glycerol, sorbitol, ethylene glycol, propylene glycol, butanediol, polymeric derivatives of vitamin E, poly(propylene), and combinations.
Aspect 12. The DHM formulation of any one of Aspects 1 through 11, further comprising a plasticizer.
Aspect 13. The DHM formulation of Aspect 12, wherein the plasticizer comprises a plasticizer selected from the group consisting of low molecular weight polyols having aliphatic hydroxyls, poly(propylene glycol), low molecular weight poly(ethylene oxide) (e.g., having an average molecular weight of less than about 500,000 Da), and poly(ethylene glycol), D-alpha tocopheryl PEG 1000 succinate (TPGS), low molecular-weight polyethylene glycol, propylene glycol, 1,2-butylene glycol, 2,3-butylene glycol, triethylene glycol, tetraethylene glycol and other poly(ethylene glycol) compounds, mono propylene glycol monoisopropyl ether, propylene glycol monoethyl ether, ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, sorbitol lactate, ethyl lactate, butyl lactate, ethyl glycolate, allyl glycolate, and combinations.
Aspect 14. The DHM formulation of any one of Aspects 12 and 13, wherein the plasticizer comprises a plasticizer selected from the group consisting of triacetin, vitamin E, pressurized CO2, citrate ester, triethyl citrate, acetyl triethyl citrate, tributyl citrate, and combinations.
Aspect 15. The DHM formulation of any one of Aspects 12 through 14, wherein the plasticizer comprises a plasticizer selected from the group consisting of a low molecular weight polymer, an oligomer, a copolymers, an oil, a small organic molecule, an ester-type plasticizer, a multi-block polymer, a single block polymer, a molecular surfactant, styrene, a glycol, a glycol ether, and combinations.
Aspect 16. The DHM formulation of any one of Aspects 1 through 15, further comprising a permeabilizer.
Aspect 17. The DHM formulation of Aspect 16, wherein the permeabilizer comprises caprylic acid, a caprylate salt, and/or sodium caprylate.
Aspect 18. The DHM formulation of any one of Aspects 16 and 17, wherein the permeabilizer comprises a permeabilizer selected from the group consisting of a fatty acid, a saturated fatty acid, and/or a fatty acid complexed with a cation, such as a metal cation, a metal divalent cation, a magnesium divalent cation, a calcium divalent cation, a zinc divalent cation, an iron divalent cation, a metal trivalent cation, an iron trivalent cation, a fatty acid salt, a fatty acid metallic soap, and combinations.
Aspect 19. The DHM formulation of any one of Aspects 1 through 18, further comprising a coactive.
Aspect 20. The DHM formulation of Aspect 19, wherein the coactive comprises an antioxidant.
Aspect 21. The DHM formulation of any one of Aspects 19 and 20, wherein the coactive is glutathione.
Aspect 22. The DHM formulation of any one of Aspects 19 through 21, wherein the coactive is L-cysteine.
Aspect 23. The DHM formulation of any one of Aspects 19 through 22, wherein the coactive is selected from the group consisting of N-acetyl cysteine (NAC), Prickly Pear extract, Milk Thistle, ginger toot, vitamin B, vitamin C, vitamin E, and combinations.
Aspect 24. The DHM formulation of any one of Aspects 19 through 23, wherein the coactive comprises an electrolyte and/or a sugar.
Aspect 25. The DHM formulation of any one of Aspects 1 through 24, further comprising a pH buffering agent.
Aspect 26. The DHM formulation of Aspect 25, wherein the pH buffering agent is an acidic pH buffering agent.
Aspect 27. The DHM formulation of Aspect 26, wherein the acidic pH buffering agent comprises citric acid, a citrate salt, a sodium citrate, a potassium citrate, calcium citrate, and/or combinations.
Aspect 28. The DHM formulation of any one of Aspects 1 through 27, wherein the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 3.5.
Aspect 29. The DHM formulation of any one of Aspects 1 through 28, wherein the DHM is not solubilized or dissolved by an aqueous solution having a pH of at most 2.
Aspect 30. The DHM formulation of any one of Aspects 1 through 29, wherein the DHM is solubilized or dissolved by an aqueous solution having a pH of at least 5.5.
Aspect 31. The DHM formulation of any one of Aspects 1 through 29, wherein the DHM is solubilized or dissolved by water or an aqueous solution having a pH of at least 7.
Aspect 32. The DHM formulation of any one of Aspects 1 through 31, wherein the DHM comprises at least 5 wt % of the powder.
Aspect 33. The DHM formulation of any one of Aspects 1 through 31, wherein the DHM comprises at least 20 wt % of the powder.
Aspect 34. The DHM formulation of any one of Aspects 1 through 31, wherein the DHM comprises at least 40 wt % of the powder.
Aspect 35. The DHM formulation of any one of Aspects 1 through 31, wherein the DHM comprises at least 55 wt % of the powder.
Aspect 36. The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 20%
Aspect 37. The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 10%.
Aspect 38. The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 5%.
Aspect 39. The DHM formulation of any one of Aspects 1 through 35, wherein the crystallinity of the DHM is at most 2%.
Aspect 40. The DHM formulation of any one of Aspects 1 through 35, wherein the DHM is amorphous.
Aspect 41. The DHM formulation of any one of Aspects 1 through 40, wherein the DHM formulation is homogeneous and/or molecularly dispersed.
Aspect 42. A dosage form, comprising - the DHM formulation of any one of Aspects 1 through 41, and
- an enteric coating that encapsulates the DHM formulation.
- Aspect 43. The dosage form of Aspect 42, wherein the enteric coating is a polymeric coating.
Aspect 44. The dosage form of Aspect 42, wherein the enteric coating is a methacrylate copolymer coating.
Aspect 45. The dosage form of any one of Aspects 42 through 44, wherein the dosage form is a capsule, tablet, or pill.
Aspect 46. A dosage form, comprising - the DHM formulation of any one of Aspects 1 through 41 in a powder form, and
- an aqueous liquid,
- wherein the DHM formulation in a powder form is mixed with or suspended in the liquid.
- Aspect 47. A dosage form, comprising
- the DHM formulation of any one of Aspects 1 through 41 in a powder form, and
- a gel,
- wherein the DHM formulation in a powder form is mixed with or suspended in the gel.
- Aspect 48. The DHM formulation of Aspect 1,
- wherein the matrix material is polyethylene oxide (PEO), and
- wherein the DHM comprises at least 5 wt % of the DHM formulation.
- Aspect 49. The DHM formulation of Aspect 1,
- wherein the matrix material is hydroxypropyl methylcellulose (HPMC), and
- wherein the DHM comprises at least 5 wt % of the DHM formulation.
- Aspect 50. A method for forming a dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47, comprising:
- mixing the dihydromyricetin (DHM) and the matrix material to form a compounding mixture;
- processing the compounding mixture in an extruder to form an extrudate; and
- collecting the extrudate as the dihydromyricetin (DHM) formulation.
- Aspect 51. The method of Aspect 50, further comprising grinding the extrudate into a powder.
Aspect 52. The method of Aspect 51, further comprising filling the powder into a capsule or pressing the powder into a tablet.
Aspect 53. The method of Aspect 50, comprising, - mixing the dihydromyricetin (DHM) and polyethylene oxide (PEO) as the matrix material to form the compounding mixture;
- wherein the weight ratio of DHM to PEO is 5:95,
- processing the compounding mixture in the extruder to form the extrudate; and
- collecting the extrudate as the dihydromyricetin (DHM) formulation.
- Aspect 54. The method of Aspect 50, comprising,
- mixing the dihydromyricetin (DHM) and hydroxypropyl methylcellulose (HPMC) as the matrix material to form the compounding mixture;
- wherein the weight ratio of DHM to HPMC is 5:95,
- processing the compounding mixture in the extruder to form the extrudate; and
- collecting the extrudate as the dihydromyricetin (DHM) formulation.
- Aspect 55. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use as a medicament.
Aspect 56. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in reducing hangover symptoms.
Aspect 57. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing an alcohol use disorder.
Aspect 58. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing alcoholism.
Aspect 59. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating an alcohol use disorder.
Aspect 60. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating alcoholism.
Aspect 61. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating an alcohol overdose.
Aspect 62. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in increasing antioxidant capacity.
Aspect 63. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in neuroprotection.
Aspect 64. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing Alzheimer's disease.
Aspect 65. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating Alzheimer's disease.
Aspect 66. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in inhibiting inflammation.
Aspect 67. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in protection of the kidney.
Aspect 68. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in protection of the liver.
Aspect 69. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing or treating cancer.
Aspect 70. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in ameliorating a metabolic disorder.
Aspect 71. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in preventing diabetes.
Aspect 72. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating diabetes.
Aspect 73. The dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 or the dosage form according to any one of Aspects 42 through 47 for use in treating a bacterial infection.
Aspect 74. Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for reducing hangover symptoms.
Aspect 75. Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for preventing an alcohol use disorder, preventing alcoholism, treating an alcohol use disorder, treating alcoholism, and/or treating an alcohol overdose.
Aspect 76. Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for neuroprotection, preventing Alzheimer's disease, and/or treating Alzheimer's disease.
Aspect 77. Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for ameliorating a metabolic disorder, preventing diabetes, and/or treating diabetes.
Aspect 78. Use of the dihydromyricetin (DHM) formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49 in the manufacture of a medicament for increasing antioxidant capacity, inhibiting inflammation, protecting the kidney, protecting the liver, preventing and/or treating cancer, and/or treating a bacterial infection.
Aspect 79. The DHM formulation of any one of Aspects 1 through 41, Aspect 48, and Aspect 49, so that mixing of the DHM formulation with a solvent results in a concentration of DHM dissolved in the solvent that is at least 20%, 50%, 70%, 100%, 200%, 400%, or 900% greater than the equilibrium concentration of crystalline DHM dissolved in the solvent.
Aspect 80. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent.
Aspect 81. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0.
Aspect 82. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM.
Aspect 83. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM and a surfactant at a concentration of from 0.01 wt % to 2 wt %.
Aspect 84. The DHM formulation of Aspect 79, wherein the solvent is an aqueous solvent of pH in the range of 4.5 to 7.0 and comprising sodium at a concentration of from 100 mM to 400 mM and a nonionic surfactant at a concentration of from 0.05 wt % to 1.5 wt %.
Aspect 85. The DHM formulation of Aspect 79, wherein the solvent is fed state simulated intestinal fluid (FeSSIF).
Aspect 86. The DHM formulation of Aspect 79, wherein the solvent is fed state simulated intestinal fluid (FeSSIF) further comprising polysorbate at a concentration of about 1 wt %.
Aspect 87. The DHM formulation of Aspect 79, wherein the solvent is fasted state simulated intestinal fluid (FaSSIF).
Aspect 88. The DHM formulation of Aspect 79, wherein the solvent is fasted state simulated intestinal fluid (FaSSIF) further comprising polysorbate at a concentration of about 1 wt %. - The following example(s) provide descriptions of embodiments of the invention. It is recognized that departures from the disclosed embodiment may be made within the scope of the invention and that obvious modifications will occur to a person skilled in the art. The claims and specification should not be construed to unduly narrow the full scope of protection to which the invention is entitled.
- An amount of dihydromyricetin (DHM) sufficient to provide an effective amount of the formulation may be mixed with a known amount of polyethylene oxide (PEO) polymer. The weight ratio of DHM to polymer may be about 5:95. The mixture may then be placed into an extruder hopper. The extruder used should include a solids-conveying mechanism (e.g., a screw or twin screws) that extends from the hopper through a heating zone to the extrusion die. The mixture is passed through the heated extruder at a temperature range which may be from about 100° C. to about 140° C., as set by the temperature setting of the extruder heating zone, so that melting or softening of the PEO occurs. Upon exiting the die, the extrudate (PEO/DHM) may be chopped to the desired length. The extrudate may then be, for example, ground to a powder and filled into a capsule or pressed into a tablet.
- An amount of dihydromyricetin (DHM) sufficient to provide an effective amount of the formulation may be mixed with a known amount of cellulose-derived AFFINISOL™ HPMC HME hydroxypropyl methylcellulose (HPMC) polymer of low to medium molecular weight.
- The weight ratio of DHM to polymer may be about 5:95. The mixture may then be placed into an extruder hopper. The extruder to be used should include a solids-conveying mechanism (e.g., a screw or twin screws) that extends from the hopper through a heating zone to the extrusion die. The mixture is passed through the heated extruder at a temperature range which may be from about 100° C. to about 155° C., as set by the temperature setting of the extruder heating zone, so that the polymer is sufficiently melted or softened. Upon exiting the die, the extrudate (HPMC/DHM) may be chopped to the desired length. The extrudate may then be, for example, ground to a powder, filled into a capsule, or pressed into a tablet.
- An amount of dihydromyricetin (DHM) sufficient to provide an effective amount of the formulation was mixed with a known amount of poly(vinylpyrrolidone-co-vinyl acetate) (PVP-VA). The PVP-VA used was BASF Kollidon VA 64, which is an amorphous copolymer having 60% vinylpyrrolidone and 40% vinyl acetate, a molecular weight of about 45,000 g/mol, and a glass-transition temperature (Tg) measured to be 109° C. The DHM and PVP-VA were mixed and ground by hand in a mortar and pestle to form a physical mixture that was fed to an extruder. A HAAKE Mini-Lab II extruder having a chamber volume of 7 cm3, counter-rotating twin screws, and an internal recirculation channel was used. Approximately 5 g of the physical mixture of DHM and PVP-VA was loaded into the extruder. The mixture was passed through the heated extruder at about 160° C., with the extruder operated at 30-50 rpm. Approximately 5 min loading time, 5 min recirculation time, and 5 min unloading time were used. The extrudate was then collected as the dihydromyricetin (DHM) formulation.
- In the exemplary extrudate produced, the drug (DHM) loading in the extrudate was 20 wt %, i.e., the weight ratio of DHM:PVP-VA was 20:80. (For example, in other cases, the weight ratio of DHM to PVP-VA may be about 5:95, 10:90, 30:70, 40:60, 50:50, 60:40, or 80:20.)
- The DHM/PVP-VA (20/80) extrudate from this hot melt extrusion (HME) was darker brown and uniform in color and somewhat opaque, indicating that the DHM was uniformly dispersed in the extrudate. The glass-transition temperature (Tg) of this DHM/PVP-VA (20/80) HME extrudate was 126° C. The PVP-VA in the DHM/PVP-VA (20/80) extrudate was amorphous.
- In comparison, extruded PVP-VA polymer (without DHM) was lighter brown in color and more translucent. The Tg of this extruded PVP-VA polymer was measured to be 108° C., the same as the bulk PVP-VA (BASF Kollidon VA64) copolymer, indicating that extrusion did not change the Tg of the polymer. The PVP-VA in the extrudate was amorphous.
- The melting temperature (point) Tm of DHM is approximately 240° C.-256° C., for example, about 240° C. Thus, the operating temperature of the extruder, about 160° C. was less than the melting temperature of the DHM. Without being bound by theory, the DHM was thought to have dissolved into the molten PVP-VA polymer in the extruder.
- The Tg of DHM is inferred to be less than 120° C. That is, a spray dried dispersion (SDD) of DHM and hydroxypropyl methylcellulose acetate succinate (HPMCAS) exhibited an intermediate Tg less than the Tg of HPMCAS (˜120° C.), so that the Tg of DHM is inferred to be less than the Tg of HPMCAS.
- Thus, the Tg of the DHM/PVP-VA (20/80) HME extrudate (126° C.) was greater than the Tg of the DHM (less than 120° C.) and was greater than the Tg of the PVP-VA matrix (about 108° C.).
- In vitro release data may be obtained to allow comparison of the concentration of DHM in a liquid yielded by starting crystalline DHM material with the concentration of DHM in a liquid yielded by a DHM—matrix HME formulation over a time period, such as a 6-hour time period with sampling timepoints at 1, 5, 10, 15, 30, 60, 120, and 360 minutes.
- For example, the release study may be performed in fed state simulated intestinal fluid (FeSSIF), with or without 1% v/v Tween 20 (Polysorbate 20) having been added. The fluid may be maintained at a temperature of 37° C. for the duration of the experiment. For each study, the starting crystalline DHM material or the HME formulation may be loaded into a separate volume of prepared FeSSIF fluid at a concentration substantially greater than the equilibrium solubility of DHM in FeSSIF (140 μg/mL). For example, the starting crystalline DHM material or the HME formulation may be loaded into the prepared FeSSIF fluid at a DHM concentration of 1400 μg/mL, 10 times the equilibrium solubility of crystalline DHM in FeSSIF, or at a DHM concentration of 7 mg/mL, 50 times the equilibrium solubility of DHM in FeSSIF. (The excess DHM loaded into the release media enables detection and quantitation of potentially supersaturated dissolved DHM concentrations that a given formulation may provide.) At the completion of the release studies, the HME formulation may be found to produce a supersaturated DHM concentration that is greater than that of the crystalline DHM.
- Such release studies may establish that the HME formulation will release a concentration of dissolved DHM into a patient's intestine that is greater than the concentration of dissolved DHM released by crystalline DHM. The greater concentration of dissolved DHM released into the patient's intestine may result in the HME formulation promoting uptake of DHM into the overall system (body) of the patient that is greater than the DHM uptake when crystalline DHM is administered, by way of an increased concentration driving force of the DHM across the membrane of the intestine.
- The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. All examples presented are representative and non-limiting. The above described embodiments of the invention may be modified or varied, without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore to be understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.
-
- 1. Powell, B. A. R., COMPOSITIONS AND METHODS FOR PREVENTING AND RECOVERY FROM DETRIMENTAL EFFECTS OF ALCOHOL CONSUMPTION, U.S. Pat. No. 9,603,830, (Mar. 28, 2017), THRIVEPLUS LLC: USA.
- 2. Shen, Y., et al., Dihydromyricetin As a Novel Anti Alcohol Intoxication Medication. The Journal of Neuroscience, 2012. 32(1): p. 390-401.
- 3. Breitenbach, J., Melt extrusion: from process to drug delivery technology. European Journal of Pharmaceutics and Biopharmaceutics, 2002. 54(2): p. 107-117.
- 4. Chokshi, R. and H. Zia, Hot-melt extrusion technique: a review. Iranian Journal of Pharmaceutical Research, 2010: p. 3-16.
- 5. Crowley, M. M., et al., Pharmaceutical applications of hot-melt extrusion: part I. Drug development and industrial pharmacy, 2007. 33(9): p. 909-926.
- 6. Maniruzzaman, M., et al., A review of hot-melt extrusion: process technology to pharmaceutical products. ISRN pharmaceutics, 2012. 2012.
- 7. Patil, H., R. V. Tiwari, and M. A. Repka, Hot-Melt Extrusion: from Theory to Application in Pharmaceutical Formulation. AAPS PharmSciTech, 2015. 17(1): p. 20-42.
- 8. Liang, J., R. Olsen, and I. Spigelman, Methods of treating alcohol intoxication, alcohol use disorders, and alcohol abuse which comprise the administration of dihydromyricetin, in Google Patents. 2012, The Regents of the University of California.
- 9. Thomson, J. E., J. John V. Landry, and M. W. Zembal, HOT-MELT EXTRUSION COATING OF RANDOM COPOLYMER OF ETHYLENE AND MONO-CARBOXYLIC ACID, in Google Patents. 1966, The Dow Chemical Company: USA.
- 10. Schippers, H. and Remscheid-Lennep, APPARATUS FOR HOT MELT EXTRUSION, in Google Patents, U. PTO, Editor. 1968, Barmer Maschinenfabrik Aktiengesellschaft Wuppertal-Oberbarmen, Germany.
- 11. McGinity, J. W. and F. Zhang, Hot-melt extrudable pharmaceutical formulation in Google Patents, U. PTO, Editor. 2002, University of Texas System: USA.
- 12. Miller, D. A., et al., STABILIZED HME COMPOSITION WITH SMALL DRUG PARTICLES, in Google Patents. 2008, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, Tex. (US): USA.
- 13. Alderman, D. A. and T. D. Wolford, Sustained release dosage form based on highly plasticized cellulose ether gels, in Google Patents. 1987, The Dow Chemical Company: USA.
- 14. Brough, C., et al., THERMOKINETIC MIXING FOR PHARMACEUTICAL APPLICATIONS, in Google Patents. 2009, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, Tex. (US): USA.
- 15. Fischer, G., et al., MATRIX COMPOSITIONS FOR CONTROLLED DELIVERY OF DRUG SUBSTANCES, in Google Patents. 2007, EGALET A/S, Vaerlose (Denmark): USA.
- 16. Yang, R. K., et al., UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS, in Google Patents. 2008, MONOSOLRX LLC, Portage, Ind. (US): USA.
- 17. Fuisz, R. C., et al., POLYMER-BASED FILMS AND DRUG DELIVERY SYSTEMS MADE THEREFROM, in Google Patents. 2007: USA.
- 18. Bernstein, H., et al., MATRICES FORMED OF POLYMER AND HYDROPHOBC COMPOUNDS FOR USE IN DRUG DELIVERY, in Google Patents, U. PTO, Editor. 2004, Acusphere, Inc., Cambridge, Mass. (US): USA.
- 19. MacAllister, S. M., et al., Pharmaceutical Formulation, in Google Patents. 2004, SMITHKLINE BEECHAM CORPORATION.
- 20. McAllister, S. M., et al., PHARMACEUTICAL FORMULATION, in Google Patents. 2003, GLAXOSMITHKLINE.
- 21. Davies, D. L., et al., Recent advances in the discovery and preclinical testing of novel compounds for the prevention and/or treatment of alcohol use disorders. Alcoholism: Clinical and Experimental Research, 2013. 37(1): p. 8-15.
- 22. Liang, J., et al., Dihydromyricetin prevents fetal alcohol exposure-induced behavioral and physiological deficits: the roles of GABAA receptors in adolescence. Neurochemical research, 2014. 39(6): p. 1147-1161.
- 23. Shen, Y., et al., Dihydromyricetin as a novel anti-alcohol intoxication medication. Journal of Neuroscience, 2012. 32(1): p. 390-401.
- 24. Ji, Y., J. Li, and P. Yang, Effects of fruits of Hovenia dulcis Thunb on acute alcohol toxicity in mice. Zhong yao cai=Zhongyaocai=Journal of Chinese medicinal materials, 2001. 24(2): p. 126-128.
- 25. Fang, H.-L., et al., Treatment of chronic liver injuries in mice by oral administration of ethanolic extract of the fruit of Hovenia dulcis. The American journal of Chinese medicine, 2007. 35(04): p. 693-703.
- 26. Hase, K., et al., Hepatoprotective Effect of Hovenia dulcis THUNB. on Experimental Liver Injuries Induced by Carbon Tetrachloride or D-Galactosamine: Lipopolysaccharide. Biological and pharmaceutical Bulletin, 1997. 20(4): p. 381-385.
- 27. Ji, Y., et al., Effects of Hovenia dulcis Thunb on blood sugar and hepatic glycogen in diabetic mice. Zhong yao cai=Zhongyaocai=Journal of Chinese medicinal materials, 2002. 25(3): p. 190-191.
- 28. Okuma, Y., et al., Effect of extracts from Hovenia dulcis Thunb. alcohol concentration in rats and men administered alcohol. Journal of Japanese Society of Nutrition and Food Science (Japan), 1995.
- 29. WANG, X.-y. and Z.-t. JIANG, RESEARCH PROGRESS IN NATURAL ANTIOXIDANT DIHYDROMYRICETIN [J]. Food Research and Development, 2007. 2: p. 056.
- 30. Zhang, X., et al., Scavenging effect of dihydromyricetin on the free radicals by ESR. Modern Food Science and Technology, 2010. 26(10): p. 1040-1042, 1070.
- 31. Liu, B., et al., Characterization and antioxidant activity of dihydromyricetin-lecithin complex. European Food Research and Technology, 2009. 230(2): p. 325-331.
- 32. Aungst, B. J., Absorption enhancers: applications and advances. The AAPS journal, 2012. 14(1): p. 10-18.
- 33. Thanou, M., J. Verhoef, and H. Junginger, Oral drug absorption enhancement by chitosan and its derivatives. Advanced drug delivery reviews, 2001. 52(2): p. 117-126.
- 34. Whitehead, K., N. Karr, and S. Mitragotri, Safe and effective permeation enhancers for oral drug delivery. Pharmaceutical research, 2008. 25(8): p. 1782-1788.
- 35. Whitehead, K. and S. Mitragotri, Mechanistic analysis of chemical permeation enhancers for oral drug delivery. Pharmaceutical research, 2008. 25(6): p. 1412-1419.
- 36. Hu, J., K. P. Johnston, and R. O. Williams, Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs. Drug development and industrial pharmacy, 2004. 30(3): p. 233-245.
- 37. Zhang, Y., et al., Design and Solidification of Fast-Releasing Clofazimine Nanoparticles for Treatment of Cryptosporidiosis. Molecular pharmaceutics, 2017. 14(10): p. 3480-3488.
- 38. Onoue, S., et al., Self-micellizing solid dispersion of cyclosporine A with improved dissolution and oral bioavailability. Eur J Pharm Sci, 2014. 62: p. 16-22.
Claims (31)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/683,387 US20200147032A1 (en) | 2018-11-14 | 2019-11-14 | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
US17/943,691 US20230285352A1 (en) | 2018-11-14 | 2022-09-13 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767208P | 2018-11-14 | 2018-11-14 | |
US16/683,387 US20200147032A1 (en) | 2018-11-14 | 2019-11-14 | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/943,691 Continuation US20230285352A1 (en) | 2018-11-14 | 2022-09-13 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200147032A1 true US20200147032A1 (en) | 2020-05-14 |
Family
ID=70551482
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/683,387 Abandoned US20200147032A1 (en) | 2018-11-14 | 2019-11-14 | Dihydromyricetin hot melt extrusion formulations and methods for forming them |
US17/943,691 Pending US20230285352A1 (en) | 2018-11-14 | 2022-09-13 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/943,691 Pending US20230285352A1 (en) | 2018-11-14 | 2022-09-13 | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them |
Country Status (1)
Country | Link |
---|---|
US (2) | US20200147032A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111773210A (en) * | 2020-07-06 | 2020-10-16 | 成都植宇生物科技有限公司 | Pharmaceutical composition for improving oral bioavailability of dihydromyricetin and preparation method thereof |
US20220265600A1 (en) * | 2019-06-14 | 2022-08-25 | The Trustees Of Princeton University | Formulations of dihydromyricetin and a permeabilizer |
WO2023031887A1 (en) * | 2021-09-03 | 2023-03-09 | Alma Therapeutics Ltd | Formulations of controlled release penetrating members for drug delivery in the small intestine wall |
CN116036034A (en) * | 2023-03-31 | 2023-05-02 | 北京佳福瑞生物科技有限公司 | Composite medicament for treating neuropsychiatric diseases and preparation method thereof |
CN116270306A (en) * | 2023-03-29 | 2023-06-23 | 广东英腾生物科技有限公司 | Water-soluble dihydromyricetin, preparation method thereof and application thereof in preparing skin anti-inflammatory skin care product |
US12102614B2 (en) | 2014-05-29 | 2024-10-01 | Cheers Health, Inc. | Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60320940D1 (en) * | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS |
AU2012222825B2 (en) * | 2011-02-28 | 2016-01-21 | Technologies Khloros Inc. | Chewable vehicle for mouth absorption |
CN108524493A (en) * | 2018-06-25 | 2018-09-14 | 湖南农业大学 | Application of the dihydromyricetin promotor composition in resisting alcoholic liver oxidative damage |
-
2019
- 2019-11-14 US US16/683,387 patent/US20200147032A1/en not_active Abandoned
-
2022
- 2022-09-13 US US17/943,691 patent/US20230285352A1/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12102614B2 (en) | 2014-05-29 | 2024-10-01 | Cheers Health, Inc. | Compositions and methods for preventing and recovery from detrimental effects of alcohol consumption |
US20220265600A1 (en) * | 2019-06-14 | 2022-08-25 | The Trustees Of Princeton University | Formulations of dihydromyricetin and a permeabilizer |
CN111773210A (en) * | 2020-07-06 | 2020-10-16 | 成都植宇生物科技有限公司 | Pharmaceutical composition for improving oral bioavailability of dihydromyricetin and preparation method thereof |
WO2023031887A1 (en) * | 2021-09-03 | 2023-03-09 | Alma Therapeutics Ltd | Formulations of controlled release penetrating members for drug delivery in the small intestine wall |
CN116270306A (en) * | 2023-03-29 | 2023-06-23 | 广东英腾生物科技有限公司 | Water-soluble dihydromyricetin, preparation method thereof and application thereof in preparing skin anti-inflammatory skin care product |
CN116036034A (en) * | 2023-03-31 | 2023-05-02 | 北京佳福瑞生物科技有限公司 | Composite medicament for treating neuropsychiatric diseases and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
US20230285352A1 (en) | 2023-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230285352A1 (en) | Dihydromyricetin Hot Melt Extrusion Formulations and Methods for Forming Them | |
EP2448567B1 (en) | Drug delivery system comprising polyoxazoline and a bioactive agent | |
JP5546860B2 (en) | Method for producing a solid dispersion of a highly crystalline therapeutic compound | |
JP5087409B2 (en) | Solid pharmaceutical formulation | |
KR101387249B1 (en) | Pharmaceutical compositions containing mixtures of polymers and active agents poorly soluble in water | |
CA3143203C (en) | Formulations of dihydromyricetin and a permeabilizer | |
US20220062223A1 (en) | Dihydromyricetin spray-dried dispension formulations and methods for forming them | |
JP6453482B2 (en) | Solid dispersion | |
Madan et al. | Hot melt extrusion and its pharmaceutical applications. | |
Keen et al. | Enhancing bioavailability through thermal processing | |
KR20100134557A (en) | Solid pharmaceutical dosage form | |
TW200803866A (en) | Solid pharmaceutical dosage forms which can be administered orally and have rapid release of active ingredient | |
CN105960397B (en) | Tablet formulations of CGRP-active compounds | |
US20220175677A1 (en) | Methods of improving pharmaceutical substance solubilization and products thereof | |
WO2012116238A1 (en) | PHARMACEUTICAL FORMULATIONS OF ACETYL-11-KETO-β-BOSWELLIC ACID, DIINDOLYLMETHANE, AND CURCUMIN FOR PHARMACEUTICAL APPLICATIONS | |
CN108495620B (en) | Pharmaceutical compositions comprising phenylaminopyrimidine derivatives | |
Rojas | Excipient design by co-processing for direct compression applications | |
KR102637828B1 (en) | Solid pharmaceutical composition for the treatment of HCV | |
WO2007141806A1 (en) | Pharmaceutical formulations comprising oxcarbazepine and methods thereof | |
WO2009016608A2 (en) | Pharmaceutical compositions of fenofibrate | |
JP7378393B2 (en) | improved drug formulation | |
KR20210150501A (en) | Solid pharmaceutical composition for treating HCV | |
KR20240108528A (en) | Solid pharmaceutical compositions for treating hcv | |
CA2812665C (en) | Pharmaceutical composition for treating hcv infections | |
EP4385497A1 (en) | Antioxidant-free fixed dose combination of netupitant and palonosetron |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: THE TRUSTEES OF PRINCETON UNIVERSITY, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRUD'HOMME, ROBERT K.;CAGGIANO, NICHOLAS;SIGNING DATES FROM 20200110 TO 20200404;REEL/FRAME:058657/0198 Owner name: CHEERS HEALTH, INC., TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POWELL, BROOKS;PANSARE, VIKRAM;SIGNING DATES FROM 20200107 TO 20200131;REEL/FRAME:058657/0167 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |